<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002063.pub6" GROUP_ID="NEUROMUSC" ID="581799082012164634" MERGED_FROM="" MODIFIED="2015-10-12 11:56:32 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;The number of papers found by the current strategies in the appendices which were run on 2 December 2013 are&lt;/p&gt;&lt;p&gt;MEDLINE - 580 (92 new papers)&lt;/p&gt;&lt;p&gt;EMBASE - 256 (49 new papers)&lt;/p&gt;&lt;p&gt;Cochrane Neuromuscular Disease Group Specialized Register - 51 papers&lt;/p&gt;&lt;p&gt;CENTRAL - 73&lt;/p&gt;&lt;p&gt;The NMD Group is now following the Cochrane policy of giving the total number of references found by each database, the number of references after deduplication, the number of references selected for further review and the number meeting the inclusion criteria for the review.&lt;/p&gt;&lt;p&gt;The numbers given above are total references retrieved (and in brackets the references retrieved since the last published review).&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;The following Databases are included in the Cochrane Library. You may wish to use the results in the discussion section&lt;/p&gt;&lt;p&gt;NHSEED (NHDS Economic Evaluation Database) - 5 papers&lt;/p&gt;&lt;p&gt;DARE (Database of Abstracts of Reviews of Effectiveness) - 3 papers&lt;/p&gt;&lt;p&gt;HTA (Health Technology Assessment Database) - 4 paper&lt;/p&gt;" NOTES_MODIFIED="2015-10-12 11:55:33 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" REVIEW_NO="015" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2015-10-12 11:56:32 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE>Intravenous immunoglobulin for Guillain-Barré syndrome</TITLE>
<CONTACT MODIFIED="2015-10-12 11:56:32 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="7655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>AC</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><SUFFIX>MD FRCP FMedSci</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>rhughes11@btinternet.com</EMAIL_1><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7676 2060</PHONE_1><FAX_1>+44 20 7829 8725</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-10-12 11:56:32 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="7655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>AC</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><SUFFIX>MD FRCP FMedSci</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>rhughes11@btinternet.com</EMAIL_1><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7676 2060</PHONE_1><FAX_1>+44 20 7829 8725</FAX_1></ADDRESS></PERSON><PERSON ID="15440" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><MIDDLE_INITIALS>V</MIDDLE_INITIALS><LAST_NAME>Swan</LAST_NAME><EMAIL_1>avswan@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Neuromuscular Disease Group, MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7692 2359</PHONE_1><FAX_1>+ 44 20 7829 8725</FAX_1></ADDRESS></PERSON><PERSON ID="15454" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pieter</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>van Doorn</LAST_NAME><POSITION>Neurologist</POSITION><EMAIL_1>p.a.vandoorn@erasmusmc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Erasmus University Medical Center</ORGANISATION><ADDRESS_1>PO Box 2040</ADDRESS_1><CITY>Rotterdam</CITY><ZIP>3000 CA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 10 703 5747</PHONE_1><FAX_1>+ 31 10 703 5927</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-01-28 10:15:59 +0000" MODIFIED_BY="Richard Hughes">
<UP_TO_DATE>
<DATE DAY="2" MONTH="12" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="12" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-12 11:55:12 +0100" MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-12 11:55:12 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="22" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>An error has been corrected: an incorrect statement that small trials in children had shown more benefit from high than low dose IVIg has been deleted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-09-29 14:01:07 +0100" MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-09-29 14:01:07 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="18" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>No change to conclusions. New search with no new trials</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-09-29 14:01:03 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="2" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>Updated, and correction of minor discrepancies in figures within text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-06-18 20:12:49 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="24" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-01-28 10:15:44 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="15" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>Search updated. One new trial included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-01-24 12:48:17 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="6" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Weight of evidence added to conclusions from 'Summary of findings' table. Jean-Claude Raphael retired from authorship.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-01-24 12:48:05 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="28" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Searches repeated with new MEDLINE and EMBASE RCT filters. No new trials. 'Risk of bias' and 'Summary of findings' tables added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-06 19:52:06 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="23" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-23 21:19:27 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Searches were repeated in March 2007 and no new trials were identified.<BR/>Searches will be run again in May 2008.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-07-23 21:16:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="9" YEAR="2005"/>
<DESCRIPTION>
<P>Four new trials were included.<BR/>
<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-03-03 12:42:45 +0000" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2009-10-11 10:15:08 +0100" MODIFIED_BY="Richard Hughes">
<SOURCE MODIFIED="2009-08-19 12:51:33 +0100" MODIFIED_BY="Richard Hughes">
<NAME>King's College London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Previous host institution</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-08-19 12:52:07 +0100" MODIFIED_BY="Richard Hughes">
<NAME>MRC Neuromuscular Disease Centre, Institute of Neurology, University College London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Host institution</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-10-11 10:15:08 +0100" MODIFIED_BY="Richard Hughes">
<NAME>Erasmus Medical Centre Rotterdam</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION>
<P>Host institution</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-03-03 12:42:45 +0000" MODIFIED_BY="Ruth Brassington">
<SOURCE>
<NAME>European Neuromuscular Centre, Naarden</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-03-03 12:42:45 +0000" MODIFIED_BY="Ruth Brassington">
<NAME>Guillain-Barré Syndrome Support Group</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-12 11:55:33 +0100" MODIFIED_BY="Ruth  Brassington">
<SUMMARY MODIFIED="2015-10-12 11:55:33 +0100" MODIFIED_BY="Ruth  Brassington">
<TITLE MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington">Intravenous immunoglobulin for Guillain-Barré syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-12 11:55:33 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<B>Review question</B>
</P>
<P>Intravenous immunoglobulin (IVIg) is a treatment in which antibodies from donated blood are injected into a person's vein. We wanted to find out whether IVIg can speed up recovery from Guillain-Barré syndrome (GBS).</P>
<P>
<B>Background</B>
</P>
<P>GBS is an uncommon disease of the nerves outside the brain and spinal cord. It causes weakness, numbness and breathing difficulty. Another Cochrane review has shown that plasma exchange (PE) works better than supportive care alone in GBS. In PE, the liquid part of a person&#8217;s blood (plasma) is replaced with a plasma substitute to remove antibodies.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We included trials of IVIg compared to no treatment, dummy treatment, PE, immunoabsorption (in which specific antibodies are removed from blood) or other immune treatments. We also considered trials of IVIg added to another treatment. We found 12 trials. Some of these compared more than two treatments.</P>
<P>- Seven trials compared IVIg with PE (in 623 participants with severe GBS).</P>
<P>- One compared PE alone to PE followed by IVIg (in 249 participants).</P>
<P>- Three compared IVIg with supportive care (in a total of 75 children).</P>
<P>- One compared a two-day to a five-day IVIg treatment plan (in 51 children).</P>
<P>- One compared IVIg with immunoabsorption (in 48 participants).</P>
<P>- One compared IVIg plus immunoabsorption with immunoabsorption (in 34 participants).</P>
<P>For this review, we chose change in a disability scale after four weeks&#8217; treatment as the main measure of the effect of IVIg.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>Five of the trials comparing IVIg and PE measured change in disability. IVIg and PE produced a similar amount of improvement in disability in the 536 trial participants. This evidence was of moderate quality. Harmful effects were no more frequent with PE or IVIg, but people were more likely to finish a course of IVIg.</P>
<P>In one trial involving 249 participants who received PE or PE followed by IVIg, there was slightly more improvement from PE and IVIg together. The effect was probably not large enough to be noticeable but the results do not rule out the possibility. This evidence was of moderate quality.</P>
<P>Three studies in children suggested that IVIg speeds up recovery compared with supportive care. Only one used the disability scale. They provided low quality evidence.</P>
<P>In one small trial in children, the effect on disability appeared similar with a standard dose over two days rather than five days.</P>
<P>Giving IVIg after immunoabsorption provided no extra benefit over immunoabsorption alone. No conclusions can be drawn from the trial comparing IVIg with immunoabsorption.</P>
<P>The risk of bias in the included studies was variable.</P>
<P>More research is needed to find the best dose of IVIg in adults and children, and one trial of giving a second dose to people who otherwise would be expected to do badly is in progress.</P>
<P>The evidence is current to December 2013.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-10-12 11:55:26 +0100" MODIFIED_BY="Ruth  Brassington">
<ABS_BACKGROUND MODIFIED="2014-06-18 17:55:14 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Guillain-Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune diseases. This is an update of a review first published in 2001 and previously updated in 2003, 2005, 2007, 2010 and 2012. Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-06-19 11:10:41 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We had the following four objectives.</P>
<P>1. To examine the efficacy of intravenous immunoglobulin (IVIg) in hastening recovery and reducing the long-term morbidity from Guillain-Barré syndrome (GBS).</P>
<P>2. To determine the most efficacious dose of IVIg in hastening recovery and reducing the long-term morbidity from GBS.</P>
<P>3. To compare the efficacy of IVIg and plasma exchange (PE) or immunoabsorption in hastening recovery and reducing the long-term morbidity from GBS.</P>
<P>4. To compare the efficacy of IVIg added to PE with PE alone in hastening recovery and reducing the long-term morbidity from GBS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-12-02 21:50:52 +0000" MODIFIED_BY="Angela A Gunn">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (2 December 2013), CENTRAL (2013, Issue 12 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to November 2013) and EMBASE (January 1980 to November 2013). We checked the bibliographies in reports of the randomised trials and contacted the authors and other experts in the field to identify additional published or unpublished data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-05-08 11:32:12 +0100" MODIFIED_BY="Richard Hughes">
<P>Randomised and quasi-randomised trials of IVIg compared with no treatment, placebo treatment, PE, or other immunomodulatory treatments in children and adults with GBS of all degrees of severity. We also included trials in which IVIg was added to another treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-05-08 11:32:20 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently selected papers, extracted data and assessed quality. We collected data about adverse events from the included trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-10-12 11:55:26 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Twelve trials were found to be eligible for inclusion in this review. Seven trials with a variable risk of bias compared IVIg with PE in 623 severely affected participants. In five trials with 536 participants for whom the outcome was available, the mean difference (MD) of change in a seven-grade disability scale after four weeks was not significantly different between the two treatments: MD of 0.02 of a grade more improvement in the intravenous immunoglobulin than the plasma exchange group; 95% confidence interval (CI) 0.25 to -0.20. There were also no statistically significant differences in the other measures considered. Three studies including a total of 75 children suggested that IVIg significantly hastens recovery compared with supportive care. The primary outcome for this review, available for only one trial with 21 mildly affected children, showed significantly more improvement in disability grade after four weeks with IVIg than supportive treatment alone, MD 1.42, 95% CI 2.57 to 0.27.</P>
<P>In one trial involving 249 participants comparing PE followed by IVIg with PE alone, the mean grade improvement was 0.2 (95% CI -0.14 to 0.54) more in the combined treatment group than in the PE alone group; not clinically significantly different, but not excluding the possibility of significant extra benefit. Another trial with 34 participants comparing immunoabsorption followed by IVIg with immunoabsorption alone did not reveal significant extra benefit from the combined treatment.</P>
<P>Adverse events were not significantly more frequent with either treatment, but IVIg is significantly much more likely to be completed than PE.</P>
<P>One trial in altogether 51 children showed no significant difference when the standard dose was given over two days rather than five days.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-03-03 11:31:51 +0000" MODIFIED_BY="Ruth Brassington">
<P>A previous Cochrane review has shown that PE hastens recovery compared with supportive treatment alone. There are no adequate comparisons of IVIg with placebo in adults, but this review provides moderate quality evidence that, in severe disease, IVIg started within two weeks from onset hastens recovery as much as PE. Adverse events were not significantly more frequent with either treatment but IVIg is significantly much more likely to be completed than PE. Also, according to moderate quality evidence, giving IVIg after PE did not confer significant extra benefit. In children, according to low quality evidence, IVIg probably hastens recovery compared with supportive care alone. More research is needed in mild disease and in patients whose treatment starts more than two weeks after onset. Dose-ranging studies are also needed and one is in progress.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-09-29 14:05:48 +0100" MODIFIED_BY="Ruth  Brassington">
<BACKGROUND MODIFIED="2014-06-19 10:25:19 +0100" MODIFIED_BY="Ruth  Brassington">
<CONDITION MODIFIED="2014-06-19 10:17:54 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Guillain-Barré syndrome (GBS) is the name given to an acute paralysing disease that causes the rapid development of weakness and usually numbness of the limbs and often the facial, swallowing and breathing muscles. It is commonly due to multifocal inflammation of the spinal roots and peripheral nerves, especially their myelin sheaths. In severe cases the axons are also damaged. The weakness reaches its nadir within a few days or up to four weeks. In 25% of patients it is sufficiently severe to require the use of artificial ventilation. Between 3.5% and 12% of patients die of complications during the acute stage (<LINK REF="REF-Hughes-2005" TYPE="REFERENCE">Hughes 2005</LINK>; <LINK REF="REF-Italian-Guillain_x002d_Barr_x00e9_-Group-1996" TYPE="REFERENCE">Italian Guillain-Barré Group 1996</LINK>; <LINK REF="REF-Rajabally-2012" TYPE="REFERENCE">Rajabally 2012</LINK>; <LINK REF="REF-Yuki-2012" TYPE="REFERENCE">Yuki 2012</LINK>). Recovery takes several weeks or months. Many patients have persistent fatigue, 12% still require aid to walk one year after the onset (<LINK REF="REF-Merkies-1999" TYPE="REFERENCE">Merkies 1999</LINK>; <LINK REF="REF-Rees-1998" TYPE="REFERENCE">Rees 1998</LINK>) and 62% still notice its effect on their or their carers' lives three to six years later (<LINK REF="REF-Bernsen-1999" TYPE="REFERENCE">Bernsen 1999</LINK>).</P>
<P>The cause of GBS is still under investigation (<LINK REF="REF-Rinaldi-2013" TYPE="REFERENCE">Rinaldi 2013</LINK>; <LINK REF="REF-Yuki-2012" TYPE="REFERENCE">Yuki 2012</LINK>). The favoured hypothesis is that it is due to an autoimmune response directed against antigens in the peripheral nerves that is triggered by a preceding bacterial or viral infection. The triggering mechanism is not understood but may be the consequence of molecular mimicry whereby antibodies or T cells stimulated by antigenic epitopes on the infecting microbe cross-react with neural epitopes. In the commonest form of GBS in Europe and North America the underlying pathological process is an acute inflammatory demyelinating polyradiculoneuropathy. The responsible antigen is likely to be in the Schwann cell membrane or the myelin sheath. The axonal forms of the disease are much less common in Europe and North America but more common in China, Japan, India and Central America. In the axonal varieties the axolemma is probably the target of the immune response. Distinguishing the different forms of the disease during life is difficult but this has been attempted with neurophysiological studies (<LINK REF="REF-Hadden-1998" TYPE="REFERENCE">Hadden 1998</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-06-19 10:25:19 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Corticosteroids have been used to treat GBS because of the inflammatory, autoimmune nature of the disease. An updated Cochrane systematic review concluded that they offered no benefit apart from a possible faster recovery in one trial when intravenous methylprednisolone was given in combination with intravenous immunoglobulin (IVIg) (<LINK REF="REF-Hughes-2012" TYPE="REFERENCE">Hughes 2012</LINK>; <LINK REF="REF-van-Koningsveld-2004" TYPE="REFERENCE">van Koningsveld 2004</LINK>). Four of five randomised trials of plasma exchange (PE) reported that this treatment hastened recovery compared with supportive treatment alone (<LINK REF="REF-French-Co_x002d_operative-Group-1987" TYPE="REFERENCE">French Co-operative Group 1987</LINK>; <LINK REF="REF-French-Co_x002d_operative-Group-1992" TYPE="REFERENCE">French Co-operative Group 1992</LINK>; <LINK REF="REF-French-Co_x002d_operative-Group-1997" TYPE="REFERENCE">French Co-operative Group 1997</LINK>; <LINK REF="REF-GBS-Study-Group-1985" TYPE="REFERENCE">GBS Study Group 1985</LINK>; <LINK REF="REF-Greenwood-1984" TYPE="REFERENCE">Greenwood 1984</LINK>; <LINK REF="REF-Osterman-1984" TYPE="REFERENCE">Osterman 1984</LINK>). Its use in severe GBS has been endorsed by a consensus conference (<LINK REF="REF-NIH-Consensus-Development-1986" TYPE="REFERENCE">NIH Consensus Development 1986</LINK>). A Cochrane systematic review concluded that PE is beneficial in GBS (<LINK REF="REF-Rapha_x00eb_l-2012" TYPE="REFERENCE">Raphaël 2012</LINK>).</P>
<P>Immunoglobulin for therapeutic use (i.e. IVIg) is purified from human plasma pooled from at least 1000 donors. IVIg was introduced for the treatment of autoimmune thrombocytopenia (<LINK REF="REF-Imbach-1981" TYPE="REFERENCE">Imbach 1981</LINK>) and other autoimmune disorders including chronic inflammatory demyelinating polyradiculoneuropathy (<LINK REF="REF-Vermeulen-1985" TYPE="REFERENCE">Vermeulen 1985</LINK>). <LINK REF="REF-Kleyweg-1988" TYPE="REFERENCE">Kleyweg 1988</LINK> reported an apparently favourable response from IVIg in a pilot study in GBS. This led to the first randomised trial comparing IVIg with PE in GBS, which reported that IVIg was possibly superior (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>). Subsequent trials reviewed have confirmed that IVIg and PE have similar efficacy. In one of these trials PE followed by IVIg was compared with PE alone and IVIg alone (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>). Because PE had become the standard treatment for GBS by the time IVIg was being considered, trials comparing IVIg with placebo have rarely been undertaken (<LINK REF="STD-G_x00fc_rses-1995" TYPE="STUDY">Gürses 1995</LINK>). Very few studies and only one randomised trial have compared different doses of IVIg (<LINK REF="STD-Rapha_x00eb_l-2001" TYPE="STUDY">Raphaël 2001</LINK>) but a trial of a second course of IVIg for patients with an adverse prognostic score is in progress (<LINK REF="STD-SIDGBS-2014" TYPE="STUDY">SIDGBS 2014</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-06-18 20:09:56 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Many potential reasons for the beneficial effect of IVIg in autoimmune diseases have been proposed. Possible mechanisms in GBS include: blockade of Fc receptors on macrophages preventing antibody-targeted attack on the Schwann cell membrane and myelin; regulation of autoantibodies or cytokines by anti-idiotypic or anti-cytokine antibodies in the pooled immunoglobulin; up-regulation of the inhibitory Fc-gamma receptor IIB on B cells (<LINK REF="REF-Tackenberg-2009" TYPE="REFERENCE">Tackenberg 2009</LINK>); down-regulation of B cell activating factor (<LINK REF="REF-Bick-2013" TYPE="REFERENCE">Bick 2013</LINK>) and interference with the complement cascade or regulatory effects on T cells (<LINK REF="REF-Dalakas-2004" TYPE="REFERENCE">Dalakas 2004</LINK>). According to an alternative hypothesis, the high concentrations of circulating immunoglobulin accelerate the breakdown of immunoglobulin G (IgG). Circulating IgG is picked up by specialised receptors, FcRn, on the endothelial cell surface, which endocytose the IgG and return it intact to the circulation. Excessive amounts of IgG exceed the capacity of the recycling system and divert the excess to the lysosomes where it is broken down (<LINK REF="REF-Yu-1999" TYPE="REFERENCE">Yu 1999</LINK>).</P>
<P>All brands of immunoglobulin for intravenous use undergo extensive purification and quality control to eliminate as far as possible the risk of transmission of viral infection (<LINK REF="REF-Dalakas-2004" TYPE="REFERENCE">Dalakas 2004</LINK>). There have been rare reports of transmission of hepatitis C by brands that have now been withdrawn from the market. Current products have an excellent safety record. There have never been any instances of transmission of HIV infection. The theoretical possibility of transmission of an infective agent will always remain with any human blood product. No instances of transmission of Creutzfeldt-Jakob disease by human blood products have been recorded. Concern about this possibility led to the withdrawal of British derived plasma as a source of blood products because of the possibility of the presence of the agent causing new variant Creutzfeldt-Jakob disease. The causative agent has been transferred by a blood transfusion and may be present in the plasma fraction (<LINK REF="REF-Llewelyn-2004" TYPE="REFERENCE">Llewelyn 2004</LINK>). Adverse events after administration of IVIg do occur but are seldom serious. There is a very small risk of anaphylaxis, almost always in patients with severe immunoglobulin A deficiency, which is not usually present in GBS. Other reported side effects include headache, myalgia, transient hypotension and flushing (all of which can be corrected by slowing the infusion rate), meningism, aseptic meningitis, skin reactions (especially eczema), neutropenia, worsening of renal failure, and stroke-like episodes attributable to hyperviscosity (<LINK REF="REF-Bertorini-1996" TYPE="REFERENCE">Bertorini 1996</LINK>; <LINK REF="REF-Casteels_x002d_van-Daele-1992" TYPE="REFERENCE">Casteels-van Daele 1992</LINK>; <LINK REF="REF-Dalakas-2004" TYPE="REFERENCE">Dalakas 2004</LINK>; <LINK REF="REF-McCluskey-1990" TYPE="REFERENCE">McCluskey 1990</LINK>; <LINK REF="REF-Tan-1993" TYPE="REFERENCE">Tan 1993</LINK>; <LINK REF="REF-Whittam-1997" TYPE="REFERENCE">Whittam 1997</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-05-07 11:10:16 +0100" MODIFIED_BY="Ruth Brassington">
<P>No other systematic review of IVIg treatment for GBS is known to exist. This review was first published in 2001 and the current update completed in 2014. An overview incorporating this review of treatment for GBS was published in 2007 (<LINK REF="REF-Hughes-2007" TYPE="REFERENCE">Hughes 2007</LINK>). Maintaining this review up-to-date provides a valuable resource for people with GBS, healthcare professionals and healthcare providers and purchasers.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-05-08 11:36:13 +0100" MODIFIED_BY="Ruth Brassington">
<P>We had the following four objectives.</P>
<OL>
<LI>To examine the efficacy of intravenous immunoglobulin (IVIg) in hastening recovery and reducing the long-term morbidity from Guillain-Barré syndrome (GBS).</LI>
<LI>To determine the most efficacious dose of IVIg in hastening recovery and reducing the long-term morbidity from GBS.</LI>
<LI>To compare the efficacy of IVIg and plasma exchange (PE) or immunoabsorption in hastening recovery and reducing the long-term morbidity from GBS.</LI>
<LI>To compare the efficacy of IVIg added to PE with PE alone in hastening recovery and reducing the long-term morbidity from GBS.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-18 20:08:24 +0100" MODIFIED_BY="Ruth  Brassington">
<SELECTION_CRITERIA MODIFIED="2014-06-18 20:08:24 +0100" MODIFIED_BY="Ruth  Brassington">
<CRIT_STUDIES MODIFIED="2014-06-18 20:08:20 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We included all randomised controlled trials (RCTs) or quasi-RCTs (alternate or other systematic allocation) of IVIg compared with no treatment, placebo treatment, PE, or other immunomodulatory treatments for GBS. We also included trials in which IVIg was added to another treatment. </P>
<P>There were no limitations by language of publication.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-03-03 11:32:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>We included children and adults with GBS of all degrees of severity. We defined GBS according to internationally accepted diagnostic criteria as acute polyradiculoneuropathy, causing progressive weakness of two or more limbs, having an onset phase of not more than four weeks, and reduced or absent tendon reflexes, and lacking alternative causes (<LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>). We included studies that did not conform exactly to these criteria, provided that the authors regarded GBS or one of its synonyms, such as acute idiopathic neuropathy or acute inflammatory demyelinating polyradiculoneuropathy, as the preferred diagnosis. We noted any departure from the internationally accepted diagnostic criteria. In this update we noted the introduction of new international diagnostic criteria which may become applicable to future versions of this review if these criteria are adopted in new trials (<LINK REF="REF-Sejvar-2011" TYPE="REFERENCE">Sejvar 2011</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-06-18 17:56:59 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We included trials in which IVIg was compared with no treatment, or placebo, or PE, or any other immunomodulatory treatment. We also included trials in which IVIg was combined with another immunomodulatory treatment such as PE. The primary comparison was always between IVIg and the other treatment. Thus we did not compare PE with no treatment, which is the subject of another Cochrane review (<LINK REF="REF-Rapha_x00eb_l-2012" TYPE="REFERENCE">Raphaël 2012</LINK>). We did include the comparison of IVIg added to PE, or immunoabsorption with PE, or immunoabsorption alone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-18 20:08:24 +0100" MODIFIED_BY="Ruth  Brassington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-06-18 20:08:23 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The primary outcome measure was improvement in disability grade (<LINK REF="REF-Hughes-1978" TYPE="REFERENCE">Hughes 1978</LINK>), four weeks after randomisation. We tested the significance of the difference between IVIg and placebo or other treatments by calculating the mean difference (MD) in the meta-analysis and pooling the results from all the trials. We selected this outcome at the protocol stage of the review because it was known to be available for the two largest trials comparing PE and IVIg, and because it is a more sensitive measure than a change in proportions.</P>
<P>We accepted the disability scale used by the authors of each trial provided that it was closely similar to that described in one of the first trials (<LINK REF="REF-Hughes-1978" TYPE="REFERENCE">Hughes 1978</LINK>), or could be adapted to correspond to that scale, a scale which is now called the GBS disability scale. The scale is as follows:</P>
<OL>
<LI>healthy;</LI>
<LI>minor symptoms or signs of neuropathy but capable of manual work;</LI>
<LI>able to walk without support of a stick but incapable of manual work;</LI>
<LI>able to walk with a stick, appliance or support;</LI>
<LI>confined to bed or chair bound;</LI>
<LI>requiring assisted ventilation; and</LI>
<LI>dead.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-06-18 20:08:24 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Secondary outcome measures were:</P>
<OL>
<LI>time from randomisation until recovery of unaided walking;</LI>
<LI>time from randomisation until recovery of walking with aid;</LI>
<LI>time from randomisation until discontinuation of ventilation (for those ventilated);</LI>
<LI>mortality;</LI>
<LI>death or disability (inability to walk without aid after 12 months);</LI>
<LI>treatment-related fluctuation (defined as a period of worsening, lasting at least seven days following a period of improvement lasting at least seven days) during the 12 weeks after randomisation, or a relapse (worsening for more than seven days starting more than 12 weeks but within one year after randomisation); worsening had to involve an increase of more than five points on the Medical Research Council (MRC) sum score (<LINK REF="REF-Kleyweg-1991" TYPE="REFERENCE">Kleyweg 1991</LINK>), or an increase of one disability grade as defined above (<LINK REF="REF-Hughes-1978" TYPE="REFERENCE">Hughes 1978</LINK>);</LI>
<LI>adverse events, whether attributable to IVIg, the comparative treatment or the disease itself, during, or within one week after stopping the trial treatment, including:</LI>
<OL>
<LI>development of new infection treated with antibiotics;</LI>
<LI>haemorrhage requiring blood transfusion;</LI>
<LI>occurrence of cardiac arrhythmia requiring treatment with cardiac rate modifying drugs or pacemaker;</LI>
<LI>autonomic instability consisting of either daily variations of systolic blood pressure greater than 40 mm Hg or sudden bradycardia involving a reduction of heart rate by more than 20 beats per minute;</LI>
<LI>development of hypertension requiring drug treatment;</LI>
<LI>development of renal failure with serum creatinine &gt; 200 mmol/litre (when this occurred, possible pre-existing factors, including age, pre-treatment serum creatinine, hypovolaemia, and brand of immunoglobulin, were to be noted);</LI>
<LI>development of headache;</LI>
<LI>development of skin rash, for example palmar eczema;</LI>
<LI>development of abnormal liver function (elevation of serum liver enzyme concentrations by more than three standard deviations (SDs) above the normal mean within four weeks after randomisation, taking into account the presence of abnormal liver function before randomisation).</LI>
</OL>
</OL>
<P>The secondary outcome measures 1 to 3 above, were selected in the original protocol of this review and have been reported. However they are difficult to incorporate in a meta-analysis because they do not provide information about those who do not reach the criterion (e.g. who remain unable to walk unaided) during the trial.</P>
<P>In an earlier update of this review, we inserted a 'Summary of findings' table for the main comparison, IVIg versus PE. We selected the primary outcome for the table and the following additional outcomes: improvement by one or more disability grades after four weeks; death or disability (inability to walk without aid) after 12 months; treatment-related fluctuation; adverse events; and discontinuation of treatment before it had been completed.</P>
<P>Improvement by one or more disability grades after four weeks and discontinuation of treatment were included in the review although they had not been included in the protocol. Improvement by one or more grades is preferred by some to mean changes of the whole group as a way of expressing the primary outcome and was used in the Cochrane review of PE for GBS (<LINK REF="REF-Rapha_x00eb_l-2012" TYPE="REFERENCE">Raphaël 2012</LINK>). Discontinuation of treatment before it had been completed showed a very large, clinically important difference.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-18 17:57:35 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We updated the search of the Cochrane Neuromuscular Disease Group Specialized Register (2 December 2013), CENTRAL (2013, Issue 12 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to November 2013) and EMBASE (January 1980 to November 2013). We checked <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> on 2nd January 2014. We checked the bibliographies in reports of the randomised trials and contacted the authors and other experts in the field to identify additional published or unpublished data. The detailed searches strategies have been provided for the Cochrane Neuromuscular Disease Group Specialized Register in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, CENTRAL in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, MEDLINE in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and EMBASE in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-18 17:57:54 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY_SELECTION MODIFIED="2012-05-08 12:21:27 +0100" MODIFIED_BY="Richard Hughes">
<P>Two review authors (RACH and PAvD) checked titles and abstracts identified from the Register. The same two review authors obtained the full text of all potentially relevant studies for independent assessment, decided which trials fitted the inclusion criteria and graded their methodological quality. The same two review authors resolved disagreements about inclusion criteria by discussion and it was not necessary to consult a third author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-05-08 11:37:44 +0100" MODIFIED_BY="Richard Hughes">
<P>Two review authors (RACH and PAvD) extracted data independently onto specially designed data collection forms. The same authors resolved disagreements by reference to the original reports. We obtained some missing data from the trial authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-06-18 17:57:45 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Two review authors (RACH and PAvD) assessed the risk of bias for this update using the methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The attributes we considered were explicit diagnostic criteria, sequence generation, allocation concealment, blinding, completeness of follow-up, freedom for selective reporting and other sources of bias. We graded these items as being at low risk of bias, high risk of bias or unclear. The two review authors graded the risk of bias independently, compared the results and reached agreement about differences by consensus without the need to consult a third author.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-08-06 10:45:21 +0100" MODIFIED_BY="Richard Hughes">
<P>We would have tested for heterogeneity in the results and undertaken a sensitivity analysis on the basis of relevant features of risk of bias if heterogeneity had been shown.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-06-18 17:57:54 +0100" MODIFIED_BY="Ruth  Brassington">
<P>When possible, we calculated a treatment effect across trials using the Cochrane statistical package, Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>), and a fixed-effect model. We expressed results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes, and MDs with 95% CIs for continuous outcomes. Where the data allowed, we analysed all the primary and secondary outcomes under consideration.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-05-08 11:38:18 +0100" MODIFIED_BY="[Empty name]">
<P>We wanted to examine the effect of IVIg in the following subgroups, chosen because of their prognostic importance in previous prospective studies and trials.</P>
<OL>
<LI>Younger and older (children aged less than 18 years; adults up to 49 years of age; adults aged 50 years or more).</LI>
<LI>More severely or less severely affected (able to walk (disability grades 1 to 3), unable to walk (grade 4), and requiring ventilation (grade 5) at randomisation).</LI>
<LI>Having or not having documented relevant sensory deficit on routine neurological examination at randomisation (symptoms alone were to be ignored).</LI>
<LI>Having, or not having, a history of diarrhoea (gastroenteritis) within the six weeks before the onset of neuropathic symptoms.</LI>
<LI>Time from onset of symptoms of neuropathy to start of treatment (seven days or less after onset, more than seven and up to 14 days after onset, and more than 14 days after onset).</LI>
</OL>
<P>As expected, the presently available studies did not contain sufficient participants with clearly defined axonal as opposed to demyelinating forms of GBS, and therefore we did not use neurophysiological criteria to define subgroups.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-06-19 10:28:27 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY_DESCRIPTION MODIFIED="2014-06-18 20:08:27 +0100" MODIFIED_BY="Ruth  Brassington">
<SEARCH_RESULTS MODIFIED="2014-06-18 17:58:03 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The number of papers found by the current strategies in the appendices were MEDLINE - 580 (92 new papers), EMBASE - 256 (49 new papers), Cochrane Neuromuscular Disease Group Specialized Register - 51 papers, and CENTRAL - 73 papers. In searches up to and including the current update, we excluded nine studies after full-text review because they were not RCTs, or it was unclear whether they were RCTs (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). We identified 12 trials for inclusion (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and there is one ongoing trial (see <LINK TAG="ONGOING_STUDIES" TYPE="SECTION">Ongoing studies</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-06-18 20:08:27 +0100" MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="3">(1) Comparison of IVIg with placebo or no treatment</HEADING>
<P>We found no trials comparing IVIg with placebo.</P>
<P>We found three trials comparing IVIg with supportive treatment alone. In one with a high risk of bias, 18 children fulfilling diagnostic criteria similar to those of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK> were allocated alternately to receive either IVIg (Sandoglobulin) 1.0 g/kg daily for two days or supportive treatment alone (<LINK REF="STD-G_x00fc_rses-1995" TYPE="STUDY">Gürses 1995</LINK>). The mean (SD) age of the children treated with IVIg was 10.4 (3.5) years, and of the children not so treated was 9.5 (2.7) years. The severity of the illness at randomisation was similar. Two children in each group required ventilation, and two in the IVIg and four in the untreated group were unable to walk even with aid. The mean duration of illness at the time of randomisation was 4.6 (2.2) days in the IVIg and 4.2 (1.9) days in the untreated group. Thus, although the numbers were small, the groups were evenly matched. The change in the disability grade scale chosen as the major outcome measure for this systematic review was not estimated. After four weeks, seven of the nine participants in the IVIg group, but only two of the nine untreated participants, had recovered full strength (Fisher's exact test P = 0.057). There were no deaths in the IVIg group but one of the participants in the untreated group developed pneumonia and died of cardiac arrest four days after the start of ventilation. The median time to recover unaided walking was 15 (range 11 to 20) days in the IVIg and 24.5 (range 21 to 28) days in the untreated group (P = 0.0003, Wilcoxon Rank Sum Test), but the latter figure excludes the participant who died. After a year, all the IVIg participants had recovered but one of the eight surviving untreated participants had severe weakness and was unable to walk. There were no relapses in either group. All the participants received their planned dose of IVIg. There was no report of any adverse events related to IVIg.</P>
<P>The second trial randomised children into three groups: dexamethasone alone, dexamethasone and IVIg, and dexamethasone and PE (<LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>). The risk of bias was unclear. The dose of IVIg was 0.2 to 0.3 g/kg daily for five to six days. The IVIg participants received 4 to 5 mg dexamethasone daily for five or six days and the dose of dexamethasone was tailed off and then stopped over seven days. The dexamethasone participants received 5 to 10 mg daily for five to seven days; this was gradually reduced and stopped over 7 to 10 days. Twenty participants were treated with IVIg and corticosteroids, and 16 with corticosteroids alone, which was the only comparison relevant to this review. The participants treated with IVIg and corticosteroids achieved significant recovery (recovery of cranial nerves and respiratory function or improvement by two more grades in a muscle strength score) in a mean of 17.1 days, and those treated with corticosteroids alone in 24.8 days. The difference of 7.7 days was significant (P &lt; 0.01) in favour of IVIg.</P>
<P>The third trial randomised mildly affected children who were still able to walk unaided to receive IVIg 1 g/kg over two days or no treatment (<LINK REF="STD-Korinthenberg-2005a" TYPE="STUDY">Korinthenberg 2005a</LINK>). The risk of bias was high because there was no placebo. The randomisation process allocated 14 participants to IVIg and only seven to no treatment. There was no significant difference in the primary outcome: the median (95% CIs) maximal disease severity at nadir was 2 (2 to 5) in the IVIg and 3 (2 to 6) in the control participants (P = 0.25). However, there were significant differences favouring IVIg in the secondary outcome measures, time to onset of signs of improvement and time to improvement on a slightly expanded version of the GBS disability grade scale. The median grade on this expanded scale after four weeks was 1 (0 to 3) in the IVIg and 2 (1 to 5) in the controls (P = 0.025).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Comparison of IVIg with PE</HEADING>
<P>PE had appeared beneficial in three RCTs and a consensus conference had concluded that it is beneficial in severe GBS (see <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK>). Therefore when it was desired to test the efficacy of IVIg, it was necessary to use PE as the comparison treatment. We found seven eligible RCTs that compared IVIg with PE.</P>
<P>In the first trial (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>), 150 patients with GBS who were unable to walk 10 metres independently were randomised to receive either IVIg 0.4 g/kg daily for five days or five PEs amounting to 200 to 250 mL/kg in five sessions over 7 to 14 days. The risk of bias was high because the study was not blinded. The primary outcome measure was improvement by one or more grades after four weeks on a disability grade scale similar to that of <LINK REF="REF-Hughes-1978" TYPE="REFERENCE">Hughes 1978</LINK> and used in this systematic review. Three participants were withdrawn soon after randomisation because they were deemed ineligible. The remainder were followed for six months. According to a pre-defined stopping rule, recruitment was discontinued after randomisation of the 150<SUP>th</SUP> participant because 53% of participants in the IVIg group had improved by one or more grades after four weeks, which was considered significantly more than 34% in the PE group. The difference was 19% (95% CI -2 to 39). Comparison of the Kaplan-Meier curves indicating the proportion of participants who did not improve by one or more grades during the 180 days of follow-up also showed significantly faster improvement in the IVIg group. The median time to improve one functional grade was 27 days for IVIg and 41 days for PE. Other results are summarised with the relevant outcome measures in the <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK>.</P>
<P>In the second trial (<LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK>), 50 patients with GBS who were unable to perform manual work were randomised to receive either IVIg 0.5 g/kg daily for four days or five PEs amounting to 200 mL/kg to 250 mL/kg over 7 to 10 days. The risk of bias was high because the study was not blinded. Six participants, all in the PE group, were excluded from analysis: one failed to attend follow-up, one was found to be pregnant, one had the diagnosis revised to chronic inflammatory demyelinating polyradiculoneuropathy, and three were given IVIg after PE because of failure to improve. In our view, all these participants should have been retained in an intention-to-treat analysis, but no more information could be obtained. There was no significant difference between the groups in the outcomes measured between them. Thus 69% of the 26 participants treated with IVIg and 61% of the 18 participants treated with PE had improved after one month. The median time to improve one disability grade was 14 days in the IVIg and 16.5 days in the PE group. There were 19 adverse events in 12 participants in the PE group (including nine events in four participants during the PE procedure) and five adverse events in three participants in the IVIg group.</P>
<P>In the third trial (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>), 383 patients with GBS who were within 14 days from onset and were unable to walk five metres independently, were randomised to receive either IVIg 0.4 g/kg daily for five days or five or six PEs amounting to 250 mL/kg over the next 8 to 13 days, or the same PE regimen followed by the same IVIg regimen. The risk of bias was low because the study was blinded for the 4-week outcome assessment. Four participants who did not meet the inclusion criteria were excluded: two had other diagnoses and two were randomised after the intended 14 days from onset. Of the remaining 379 participants, 130 received IVIg alone, 121 PE alone and 128 both treatments. Follow-up data were available for all participants after four weeks, and after 48 weeks for all but one participant in the IVIg group, seven participants in the PE group, and nine in the PE followed by IVIg group. In the planned comparisons of the IVIg group with the PE group no significant differences emerged. For the primary outcome measure the mean improvement in the disability grade after four weeks was 0.8 (SD 1.3) in the IVIg group and 0.9 (SD 1.3) in the PE group. The difference was only 0.10 grade and the 95% CI of this difference was -0.22 to 0.42 less than the preset criterion for equivalence, which was therefore met. Other results are summarised with the relevant outcome measures below.</P>
<P>In the fourth trial (<LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK>), 27 patients were randomised to IVIg and 26 to PE, but four were withdrawn from the IVIg and two from the PE group and not followed up. The risk of bias was high because the study was not blinded.The IVIg given was the standard regimen of 0.4 g/kg daily for five days. The PE amounted to a total of 200 mL/kg to 250 mL/kg in up to seven sessions over four weeks. The methods of PE included ultrafiltration, centrifugation and immunoabsorption, and the number of participants undergoing each technique was not included in the report. The baseline features of the groups were judged to be adequately balanced, although the average (SD) age of the PE participants was 45 (12) years, significantly older than that of the IVIg participants which was 36 (12) years. This might have biased the result against identifying greater benefit from PE since older age has been shown to be an adverse prognostic factor in larger trials (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>; <LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>). No significant differences were found between the groups in any of the measured outcomes which included the proportion of participants improved by one or more grades after four weeks, change in disability grade after four weeks, time until improvement by one disability grade, and time until improvement by two disability grades.</P>
<P>In the fifth trial (<LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>), 25 participants were randomised to receive IVIg, 26 to PE and 23 to immunoabsorption (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The risk of bias was high because the study was not blinded. Recruitment was slow and therefore further recruitment was abandoned. Twenty-three of 25 participants randomised to IVIg completed treatment and 20 were available for analysis after four weeks compared with 26 randomised to PE all completing treatment and 21 being available after four weeks. No significant differences between the treatments were found but the small numbers and high dropout rate prevent firm conclusions.</P>
<P>The sixth trial involved 54 children randomised to receive IVIg, PE or dexamethasone (<LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>); this trial has already been mentioned. We included it in the review because it was randomised, but the report lacks information about quality criteria; no details are given about any of the outcome measures pre-selected for this review (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>The seventh trial randomised children in an intensive care unit already on mechanical ventilation to receive IVIg 0.4 g/kg daily for five days or one plasma volume PE daily for five days (<LINK REF="STD-El_x002d_Bayoumi-2011" TYPE="STUDY">El-Bayoumi 2011</LINK>). The risk of bias was high because the study was not blinded. The primary outcome was the duration of mechanical ventilation which was slightly but statistically significantly shorter in the 21 participants who received PE (median 11.0 (interquartile range 11.0 to 13.0) days) than in the 20 who received IVIg (median 13.0 (interquartile range 11.3 to 14.5) days, P = 0.037). Other outcomes, length of intensive care unit stay and ability to walk unaided within four weeks of intensive care unit discharge, were not significantly different between the treatments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(3) Comparison of IVIg added to PE with PE alone</HEADING>
<P>In the third trial mentioned above (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>), the IVIg alone group was compared with the PE followed by IVIg group. In the planned comparisons no significant differences emerged unless covariates were taken into account. For the primary outcome measure, the mean (SD) improvement in the disability grade after four weeks was 0.8 (1.3) in the IVIg group and 1.1 (1.4) in the PE plus IVIg group. The difference was only 0.2 of a grade and the 95% CI of this difference was -0.14 to 0.54. The upper boundary of the 95% CI exceeded 0.5 which was the preset criterion for equivalence. There was therefore no significant difference between the groups but it was not possible to exclude the possibility of a 0.5 grade advantage to the PE plus IVIg group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(4) Comparison of IVIg added to immunoabsorption with immunoabsorption alone</HEADING>
<P>A comparison between IVIg and PE or immunoabsorption followed by IVIg was reported in blocks of sequentially treated patients in <LINK REF="STD-Haupt-1996" TYPE="STUDY">Haupt 1996</LINK>. In the first block, 11 participants were treated with PE totalling 2.0 to 2.5 L over a mean of 7.9 sessions. In the second block, 13 participants had plasma separated totalling 1.5 to 3.7 L during a mean of 6.1 sessions, and then selectively absorbed. The absorption columns were polyvinyl exchange columns to which tryptophan had been covalently bound. In the third block of 21 participants, selective absorption was followed by IVIg (Sandoglobulin) 0.4 g/kg daily for five days. Since comparison of the PE group with the immunoabsorption group showed no differences, the authors combined the two groups and compared them with the group treated first with immunoabsorption and then with IVIg. According to this analysis there was a significant difference in favour of the sequentially treated group. The improvement in disability grade after four weeks was 1.6 (SD 1.63) grades in the sequentially treated group and only 0.5 (1.02) grades in the combined PE/immunoabsorption groups (P = 0.02). We questioned the validity of combining the results of the PE and immunoabsorption groups for this analysis. Furthermore, the block sequential design did not permit allocation concealment or blinding of observers and may have failed to control for unidentified factors affecting prognosis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(5) Comparison of IVIg with immunoabsorption</HEADING>
<P>One trial compared IVIg with immunoabsorption and with PE in three parallel groups (<LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>, see above). Twenty-three of 25 participants randomised to IVIg completed treatment and 20 were available for analysis after four weeks, compared with 18 of 23 randomised to immunoabsorption completing treatment and 14 being available after four weeks. No significant differences between the treatments were found but the very small numbers and high dropout rate prevent firm conclusions. In the trial of <LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK> mentioned above, an unknown number of the participants in the PE group had their 'PE' undertaken using the immunoabsorption technique. There was no significant difference between the groups in any of the outcomes measured.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(6) Comparison of different doses of IVIg</HEADING>
<P>One trial compared 0.4 g/kg of IVIg daily for three days with the same dose daily for six days (<LINK REF="STD-Rapha_x00eb_l-2001" TYPE="STUDY">Raphaël 2001</LINK>). This was a high quality randomised double-blind trial with a low risk of bias involving 39 participants. Unfortunately it was terminated prematurely because of a national directive not to use albumin as a placebo. Nevertheless the results showed a trend in favour of the higher dose (see <LINK TAG="ADDITIONAL_TABLES" TYPE="SECTION">Additional tables</LINK> and <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK>). Another trial with 51 participants compared 1.0 g/kg daily for two days with the standard regimen of 0.4 g/kg daily for five days, giving the same total dose to each (<LINK REF="STD-Korinthenberg-2005b" TYPE="STUDY">Korinthenberg 2005b</LINK>). This was a randomised open study in children. There were no significant differences in the primary or secondary outcome measures reported by the authors (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) except that early relapses were significantly more common after the two-day (5/23) than the five-day regimen (0/23 P = 0.049).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-05-07 16:41:38 +0100" MODIFIED_BY="Ruth Brassington">
<P>The risk of bias varied between studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The principal problem in the two large trials was the absence of blinding. This was overcome in the <LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK> trial by having a blinded observer collect the primary outcome data after four weeks, but this was not done in the <LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK> trial.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-06-19 10:28:27 +0100" MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="3">(1) Comparison of IVIg with placebo or no treatment</HEADING>
<P>We found no trials comparing IVIg with placebo. We found three trials comparing IVIg with supportive treatment, all in children. One (<LINK REF="STD-G_x00fc_rses-1995" TYPE="STUDY">Gürses 1995</LINK>) compared IVIg with supportive treatment alone (see <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK> above). This was a quasi-randomised trial with inadequate allocation concealment. The number of participants included was 18, too few to permit robust conclusions. Our disability grade scale was not used. The second trial randomised children into three groups: dexamethasone alone, dexamethasone and IVIg, and dexamethasone and PE (<LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>). This included 20 children treated with IVIg and corticosteroids, and 16 with corticosteroids alone, who are relevant to this comparison. The children who received IVIg recovered muscle strength significantly faster than those treated without (see <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>) but the report lacked any of the outcome measures selected for this systematic review. The third trial ((<LINK REF="STD-Korinthenberg-2005a" TYPE="STUDY">Korinthenberg 2005a</LINK>) was a randomised open study that compared IVIg at a dose of 1.0 g/kg (half the usual dose) in mildly affected children who could still walk unaided. The authors made available the detailed results from which we were able to compute the change in our disability grade scale after four weeks. This was significantly greater in the IVIg than the untreated participants (MD -1.42, 95% CI -2.57 to -0.27, see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Comparison of IVIg with PE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(a) Improvement in disability grade four weeks after randomisation</HEADING>
<P>We combined the results of the five trials for which this primary outcome measure was available in a meta-analysis in which 273 participants had been treated with IVIg and 263 with PE. In order to calculate the MD of the improvement in disability grade we have imputed the largest values of the SD for any of the other trials with that intervention for the SDs of two trials for which the figure was not available (<LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK>; <LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>). There was -0.02 of a grade more improvement with IVIg than with PE (95% CI -0.25 more improvement to 0.20 less improvement) (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). As an alternative method of examining this outcome, we compared the number of participants who had improved one disability grade four weeks after randomisation. The RR of improvement was 1.08 (95% CI 0.94 to 1.23) more with IVIg than with PE (see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Time from randomisation until recovery of unaided walking</HEADING>
<P>In one of the two trials (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>) for which data were available, the median times were similar, 51 (95% CI 39 to 74) days in the IVIg group and 49 (95% CI 29 to 68) days in the PE group. In the other trial (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>), the median (95% CI) time was shorter in 74 participants in the IVIg group, 55 (30 to 70) days compared with 69 (55 to 97) days in 73 participants in the PE group. The P value of the difference in that trial was 0.07. Without the raw data there is no recognised standard way to combine and test differences between medians. However, the <LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK> trial result marginally favoured PE so that a formally correct pooling procedure, if one were available, would be unlikely to show a significant difference.</P>
<P>This outcome was not available for the other five trials, but for one trial (<LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK>) a related outcome, time to recover the ability to do manual work, was available and was shorter in the IVIg than in the PE group, median 65 compared with 90 days. The difference between the groups was stated by the authors not to be significant when disability grade at randomisation was included as a covariate in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) Time from randomisation until recovery of walking with aid</HEADING>
<P>This time was not available for any of the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(d) Time from randomisation until discontinuation of ventilation (for those ventilated)</HEADING>
<P>In the <LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK> trial the median (95% CI) time to discontinuation of ventilation was 27 (13 to 97) days in 29 ventilated participants in the IVIg group and 34 (12 to 97) days in 34 ventilated participants in the PE group. In the <LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK> trial the median time to discontinuation of ventilation was 26 (95% CI 18.4 to 38.2) days in 44 ventilated participants in the IVIg group and 29 (95% CI 19.1 to 45.9) days in the 40 ventilated participants in the PE group. One other trial gave data for this outcome (<LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>) but only three participants in each group received ventilation (6, 30 and 64 days in the PE group and 9, 34 and 142 days in the IVIg group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(e) Mortality</HEADING>
<P>There were seven deaths out of the 316 IVIg treated participants and nine out of 307 PE participants. There were fewer deaths among the IVIg treated participants, RR 0.78 (95% CI 0.31 to 1.95) (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> ). This analysis included the whole follow-up period, which differed between studies: three months in the <LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK> trial, six months in the <LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK> trial, one year in the <LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK> trial, 48 weeks in the <LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK> trial and not stated in the <LINK REF="STD-El_x002d_Bayoumi-2011" TYPE="STUDY">El-Bayoumi 2011</LINK> trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(f) Death or disability (inability to walk without aid) after 12 months</HEADING>
<P>This outcome measure was available only in the largest trial (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>). In that trial 21 of 129 IVIg participants and 19 of 114 PE participants were dead or so disabled that they required aid to walk after 48 weeks, a non-significant difference (see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(g) Treatment related fluctuations or relapses</HEADING>
<P>In the two largest trials for which combined data were available (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>; <LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>), there were 12 of 204 IVIg participants and 13 of 194 PE participants with either relapses or treatment-related fluctuations. These proportions give a RR of 0.89 (95% CI 0.42 to 1.89) (see <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Relapses were not mentioned in the other trials so it is impossible to be sure that they were recorded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(h) Proportion of participants with adverse events</HEADING>
<P>It was not possible to identify adverse events as envisaged in the original protocol and methods section of this review. The following describes the adverse events that were reported in five trials.</P>
<P>In the first trial (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>), there were more instances of pneumonia, atelectasis, thrombosis and haemodynamic difficulties in the PE than the IVIg group. The numbers of individual complications were not stated but there were 49 in the IVIg group and 68 in the PE group. There were multiple complications in 5 of 74 IVIg and 16 of 73 PE participants (RR 0.31, 95% CI 0.12 to 0.80) (see <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). The incidents related to IVIg were hypotension not requiring treatment in two, dyspnoea in one, fever in one and haematuria in one. Elevated serum alanine aminotransferase concentrations were present in 30% of the PE and 21% of the IVIg participants at study entry and in 42% of the PE and 63% of the IVIg participants after two weeks. By two weeks after entry the median concentration was 1.02 times the upper limit of normal in the PE group and significantly greater, 2.03 times the upper limit of normal, in the IVIg group (P = 0.02). In the second trial (<LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK>) there were five complications in the 26 IVIg participants and 19 complications in the 18 PE participants, which the authors stated showed a trend in favour of the IVIg group (P = 0.07). Since the authors did not state how many individuals had complications we could not include these figures in the meta-analysis. In the third trial (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>), adverse events attributed to treatment occurred in 6 of 130 IVIg and 8 of 121 PE participants. In the IVIg group these adverse events were nausea or vomiting in two participants, and meningism, exacerbation of chronic renal failure, possible myocardial infarction, and painful erythema at the infusion site in one each. In the PE group the adverse events were hypotension in five, and septicaemia, pneumonia, malaise, abnormal clotting and hypocalcaemia in one each. In the fourth trial (<LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK>) adverse events occurred in 5 of 23 IVIg and 7 of 24 PE participants. In the fifth trial (<LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>) there were adverse events in 12 of 23 IVIg and 14 of 26 PE participants (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). There were no adverse events in the 41 participants in the <LINK REF="STD-El_x002d_Bayoumi-2011" TYPE="STUDY">El-Bayoumi 2011</LINK> trial. We performed a meta-analysis from the results of the last four trials involving 388 participants (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The RR was 0.84 (95% CI 0.54 to 1.30) fewer participants with adverse effects in the IVIg group than in the PE treated group. The definition of adverse events and ascription of causality was not uniform between trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(i) Subgroup analysis</HEADING>
<P>Analyses of some of the planned subgroups were possible in two trials.</P>
<P>The first trial (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>) tested the effect of age, sex, antecedent gastrointestinal infection, antecedent upper respiratory infection, time from onset of weakness until start of treatment, distribution of weakness (predominantly distal, proximal, global or mixed), disability grade, Medical Research Council sum score, presence of sensory loss and cranial nerve deficits, and electrophysiological parameters on treatment response. In a multivariable analysis only antecedent diarrhoea affected treatment response. Participants with diarrhoea who received IVIg had a significantly better outcome than those who received PE.</P>
<P>In the second trial (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>), two of the subgroups selected for consideration in this review, age (adults up to 49; adults older than 49 years) and sensory deficit at entry had no significant effect on the treatment response, as measured by the change in disability grade after four weeks. However, in contradiction to the result of the first trial, those who had a history of diarrhoea responded better to PE than to IVIg (see <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>). There was also some evidence that those entering the trial with more severe disability (grade five) responded better to PE than IVIg (see <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK> ). Reasons for interpreting this exploratory analysis with caution are mentioned in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
<P>Although not included in our protocol, we consider that a subgroup analysis of the effects in children is appropriate. The <LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK> study compared 20 children who received IVIg with 18 who received PE. Both groups received dexamethasone (see <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>). The outcome measures specified for this review were not available, but the children who received IVIg achieved recovery of bulbar or respiratory function or a two-grade improvement in muscle strength in a mean (SD) of 17 (6) days compared with 30 (7) days in the PE group (P &lt; 0.0001). In the <LINK REF="STD-El_x002d_Bayoumi-2011" TYPE="STUDY">El-Bayoumi 2011</LINK> trial in severely affected children, there was a similar high rate of improvement, by at least one disability grade, with PE as with IVIg (RR 0.94, 95% CI 0.79 to 1.13, see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) while the duration of mechanical ventilation was slightly but significantly shorter with PE than with IVIg, as described above.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(3) Comparison of IVIg added to PE with PE alone</HEADING>
<P>Only one trial compared these regimens (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">(a) Improvement in disability grade four weeks after randomisation</HEADING>
<P>There was a MD of -0.20 (95% CI -0.54 to 0.14) of a grade more improvement in the 128 participants who received both treatments than in the 121 participants who received PE alone (see <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Time from randomisation until recovery of unaided walking</HEADING>
<P>The median (inter-quartile range) time to recover unaided walking was 40 (19 to 137) days in the 128 participants who received both treatments and 49 (19 to 148) days in the 121 participants who received PE alone. When these times were compared in a survival curve analysis using the log rank test the difference was not significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) Time from randomisation until recovery of walking with aid</HEADING>
<P>This time was not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(d) Time from randomisation until discontinuation of ventilation (for those ventilated)</HEADING>
<P>The median (inter-quartile range) duration of ventilation was 18 (10 to 56) days in 41 participants in the combined treatment group and 29 (14 to 57) days in 40 participants in the PE group. When these times were compared in a survival curve analysis using the log rank test the difference was not significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(e) Mortality</HEADING>
<P>Eight of 128 participants in the combined treatment group died compared with 5 of 121 participants in the PE group during the 48 weeks of follow-up (RR 1.51, 95% CI 0.51 to 4.50) (see <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(f) Proportion of participants dead or disabled (unable to walk without aid after 12 months)</HEADING>
<P>Seventeen of 122 participants in the combined treatment group were dead or disabled after 48 weeks compared with 19 of 114 participants in the PE group during the 48 weeks of follow-up (RR 0.84, 95% CI 0.46 to 1.53) (see <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(g) Proportion of participants with treatment-related fluctuation or relapse</HEADING>
<P>The combined outcome of treatment-related fluctuation or relapse occurred in 9 of 128 in the combined treatment group and 7 of 121 in the PE alone group (RR 1.22, 95% CI 0.47 to 3.16) (see <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(h) Proportion of participants with adverse events</HEADING>
<P>The adverse events in our original protocol and described in the methods section were not available. In the combined treatment group, 6 of 128 participants had complications attributed to PE. These were hypotension in three and pulmonary oedema, retroperitoneal haemorrhage, and endocarditis with cerebral embolism in one each. There were also nine participants who had complications attributed to IVIg. These were rigor in four, fever in two, and flu-like symptoms, malaise with nausea and myalgia, hypotension and chest pain in one each. In the PE group, complications were attributed to PE in 8 of 121 participants. The complications were hypotension in five and septicaemia, pneumonia, malaise, abnormal clotting and hypocalcaemia in one each. Some participants had more than one complication.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(4) Comparison of IVIg added to immunoabsorption with immunoabsorption alone</HEADING>
<P>One trial compared these regimens (<LINK REF="STD-Haupt-1996" TYPE="STUDY">Haupt 1996</LINK>). Only the available outcome measures relevant to this review have been reproduced here.</P>
<SUBSECTION>
<HEADING LEVEL="4">(a) Improvement in disability grade four weeks after randomisation</HEADING>
<P>Twenty-one participants treated with immunoabsorption followed by IVIg improved by 1.60 grades. Thirteen participants treated with immunoabsorption alone improved by 0.50 of a grade. The MD was 1.10 (95% CI 0.32 to 1.88) more improvement in the immunoabsorption followed by IVIg group (see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Mortality</HEADING>
<P>There were no deaths in either group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) Dead or disabled after one year</HEADING>
<P>This outcome was not given, but the mean (SD) disability grade after 12 months was not significantly different, being 0.40 (0.60) in the 21 participants treated with immunoabsorption followed by IVIg and 0.50 (0.52) in the 13 participants treated with immunoabsorption alone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(d) Adverse events</HEADING>
<P>In the combined treatment group there was an allergic reaction in one, hypotension in four, and coagulopathy in five of the 21 participants. Three participants developed pneumonia and two developed urinary tract infections. There were allergic reactions in three, hypotension in two, electrolyte imbalance in one and cerebral infarction in one of the 13 participants treated with immunoabsorption. In addition, three developed pneumonia and one developed gastrointestinal infection.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(5) Comparison of IVIg with immunoabsorption alone</HEADING>
<P>The one trial of this comparison included 25 participants treated with IVIg and 23 treated with immunoabsorption (<LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>). It showed no significant difference in the number who improved one disability grade between the groups after four weeks or 12 months. Because of dropouts the numbers available for analysis were seriously reduced. The authors' own primary outcome measure was the number improved by at least one GBS disability grade after four weeks, which was 16 of 20 participants in the IVIg group and 7 of 14 participants in the immunoabsorption group (RR 1.60, 95% CI 0.91 to 2.82). We calculated mean grade changes and imputed values for their SDs and found no significant differences (see <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). There were no deaths in the IVIg group and one death from pulmonary embolism in the immunoabsorption group (see <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(6) Comparison of different doses of IVIg</HEADING>
<P>One trial compared three days with six days of IVIg 0.4 g/kg in 39 participants with severe GBS and contraindications to PE (<LINK REF="STD-Rapha_x00eb_l-2001" TYPE="STUDY">Raphaël 2001</LINK>). The primary outcome measure for this review, the mean improvement in disability grade, was 0.50 (95% CI -0.26 to 1.26) more in the high-dose than the low-dose group (see <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). The authors' own primary outcome measure was time to walk with aid, for which the median (range) was 84 (23 to 121) days in the high-dose group and 131 (51 to 120) days in the low-dose group (P = 0.08). There were no significant differences in the time to walk without assistance, duration of ventilation, adverse events or mortality (2 out of 18 deaths in the low-dose and 4 out of 21 deaths in the high-dose group). Figures for the proportion dead or disabled after a year are not available, but full recovery of strength was non-significantly greater in the high-dose (11 out of 16) compared with the low-dose group (6 out of 15) (RR 1.72, 95% CI 0.85 to 3.47).</P>
<P>Another trial, a randomised but open study in 51 children, used the standard total dose of 2.0 g/kg in both trial arms but compared 1.0 g/kg daily for two days with the standard regimen of 0.4 g/kg daily for five days (<LINK REF="STD-Korinthenberg-2005b" TYPE="STUDY">Korinthenberg 2005b</LINK>). There were no significant differences in the primary or secondary outcome measures reported by the authors (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) except that early relapses were significantly more common after the two-day (5/23) than the five-day regimen (0/23, P = 0.049). There was no significant difference in the primary outcome measure for this review: the MD of change in disability grade after four weeks was 0.27 less improvement with the two-day than the five-day regimen but the 95% CIs were wide (-0.40 to 0.94) so that there is uncertainty about this conclusion (see <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-09-29 14:05:48 +0100" MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="2">(1) Comparison of IVIg with no treatment or placebo</HEADING>
<P>No trials compared IVIg with placebo, and only three compared IVIg with no treatment. The first trial included only 18 participants, which gives inadequate power in a disease with such a variable outcome as GBS (<LINK REF="STD-G_x00fc_rses-1995" TYPE="STUDY">Gürses 1995</LINK>). It involved only children so that the results may not be generalisable to adults, who are more likely to have worse outcomes. The trial used alternate allocation, which prevented allocation concealment, a factor known to bias outcomes. We concluded that little weight could be placed on the results of this trial. The second trial involved 54 children randomised to receive IVIg, PE or dexamethasone (<LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>). Since the children received dexamethasone 4 to 5 mg before each IVIg or PE session, this trial included the comparison of IVIg added to corticosteroids with corticosteroids alone. The result favoured IVIg but the outcome measure used a different scale from that in the other study and could not be incorporated in a meta-analysis. The third trial compared IVIg with no treatment in mildly affected children (<LINK REF="STD-Korinthenberg-2005a" TYPE="STUDY">Korinthenberg 2005a</LINK>). The primary outcome measure selected by the authors of that trial, disability grade at nadir, was not significantly different between the groups. However secondary outcome measures and the primary outcome measure for this review (change in disability grade after four weeks) significantly favoured IVIg. Confidence in this conclusion has to be tempered by the small size of the trial, imbalance of numbers between the IVIg and placebo, and open design.</P>
<P>Although not randomised and so not included in the results section or any meta-analysis, the retrospective study of <LINK REF="STD-Kanra-1997" TYPE="STUDY">Kanra 1997</LINK> deserves some consideration. It compared IVIg with supportive treatment alone. Twenty-four children in Canada received IVIg 1 g/kg daily for two days and 23 children in Turkey received 0.4 g/kg daily for five days. Twenty-eight other participants in Turkey received no IVIg and had supportive care only. The mean time to recover one grade was 17 days in the Canadian IVIg group, 21 days in the Turkish IVIg group and significantly longer, 62 days (P &lt; 0.01), in the Turkish no IVIg group.</P>
<P>The quality of all four studies was limited by their settings and the constraints of randomised trials in children, but the conclusions consistently point to a beneficial effect of IVIg in children. This is consistent with the conclusion we reach below concerning trials in adults that IVIg has equivalent efficacy to PE. In the face of this evidence, it may be questioned whether it is now necessary to perform more randomised trials of IVIg in children severely affected by GBS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">(2) Comparison of IVIg with PE</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">Equivalent efficacy</HEADING>
<P>PE was established as superior to no treatment in four of five randomised trials of PE and its use in severe GBS has been endorsed by a consensus conference (see <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK>). When we combined the results of all five trials comparing IVIg with PE and also providing data for our primary outcome measure, there was no significant difference. There was also no significant difference for any of our secondary outcome measures but not all trials reported all measures. We conclude that IVIg and PE have similar efficacy in hastening recovery from GBS. This is consistent with a non-randomised cohort study of 50 participants that was excluded from the analysis because it was not randomised. This study reported a non-significant trend in favour of more recovery after three months in 20 participants who received IVIg compared with 16 who received PE as their first treatment (<LINK REF="STD-Ravasio-1995" TYPE="STUDY">Ravasio 1995</LINK>). In the only other trial that addressed this comparison (<LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>), 18 children received PE and 20 received IVIg. The results favoured IVIg but did not include the outcome measures preselected for this review. It is unlikely that the results of this small trial would have affected the conclusion of our meta-analysis that the treatments are equivalent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>In the first trial involving 150 participants (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>), there were more instances of pneumonia, atelectasis, thrombosis and haemodynamic difficulties, and significantly more participants with multiple complications in the PE than the IVIg group. Transient elevations of serum alanine aminotransferase concentrations were also more common in the IVIg than the PE group. In the second trial, involving 50 participants randomised (with 6 dropouts) (<LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK>), there were also more participants with complications in the IVIg than the PE group. In the third trial involving 251 subjects (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>), adverse events attributed to treatment also occurred more often in those undergoing PE than in those receiving IVIg. In the fourth trial (<LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK>), adverse events occurred in 5 of 23 IVIg and 7 of 24 PE participants. In the <LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK> trial there were adverse events in 12 of 23 IVIg and 14 of 26 PE participants. In the <LINK REF="STD-El_x002d_Bayoumi-2011" TYPE="STUDY">El-Bayoumi 2011</LINK> trial with 20 IVIg and 21 PE participants, no adverse events were reported. The non-uniformity between trials of criteria for classifying adverse events and their causality reduced the value of any comparison. However, a meta-analysis from the the last four trials involving 388 participants showed fewer participants with adverse effects in the IVIg than in the PE treated participants (RR 0.84, 95% CI 0.54 to 1.30), a non-significant difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ease of treatment</HEADING>
<P>In the largest trial (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>), treatment was curtailed by at least 25% in 18 of 121 PE and 3 of 130 IVIg participants, a highly significant difference. In the Dutch trial one or more sessions of PE were discontinued in 12 of 73 participants, whereas the IVIg courses were completed according to protocol in all 74 participants randomised to that treatment (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>). In the <LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK> trial all 50 participants completed their IVIg or PE according to the protocol. In the <LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK> trial, one of 23 IVIg and one of 24 PE participants discontinued treatment. It was not stated whether any participants discontinued treatment in the <LINK REF="STD-El_x002d_Bayoumi-2011" TYPE="STUDY">El-Bayoumi 2011</LINK> trial. We compared the proportions of participants who discontinued treatment in a meta-analysis that had not been planned in our protocol. The risk ratio (RR) of treatment being discontinued was 0.14 less in the IVIg than in the PE group (95% CI 0.05 to 0.36) (see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). This highly significant difference was expected because giving IVIg is simple compared with PE, which requires access to two veins (of which one has to permit high flow volumes and often requires the insertion of a central venous line), a PE machine and specially trained personnel. IVIg needs access to only a single peripheral vein and no special equipment or specially trained staff.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>The analyses of the preselected subgroups require further consideration. For age and sensory deficit, no significant differences emerged in either of the large trials. For those with diarrhoea there were significant differences in the two largest trials but the differences were in opposite directions. Participants with diarrhoea had significantly more benefit on the primary outcome measure of the change in disability grade when treated with IVIg than with PE in one trial (<LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>) and with PE than with IVIg in the other (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>). However since IVIg appeared more efficacious in one trial and PE in the other, the differences detected are likely to have been chance findings. Although the disability grade at randomisation did not have a significant effect on prognosis in either of these trials, analysis of the primary outcome measure in the subgroup of participants who were already being ventilated at the time of randomisation in the <LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK> trial did show significantly less improvement in the IVIg group than the PE group (see <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). This difference should be interpreted with caution for several reasons: the trial included three groups and is only one of many analyses that have been performed; this analysis was exploratory and was not planned in the original trial protocol but was required by the protocol for this review; and furthermore, there was no indication of such a difference in the participants with lesser disability. In the <LINK REF="STD-El_x002d_Bayoumi-2011" TYPE="STUDY">El-Bayoumi 2011</LINK> trial, there was a marginal trend for fewer IVIg than PE participants to improve by at least one grade by four weeks (RR 0.94, 95% CI 0.79 to 1.13, see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Other subgroups have been investigated in non-randomised series but were not predetermined for this systematic review, and data were not available from other trials in order to perform a meta-analysis. Yuki and colleagues identified 25 patients with antibodies to ganglioside GM1b and found that the 10 treated with IVIg recovered unaided, walking faster than those treated with PE (P &lt; 0.001) (<LINK REF="REF-Yuki-2000" TYPE="REFERENCE">Yuki 2000</LINK>). The same authors reported that in a retrospective study, of 24 patients with antibodies to the closely related ganglioside GM1, 10 treated with IVIg recovered unaided, walking faster than 14 treated with PE (P &lt; 0.05) (<LINK REF="REF-Kuwabara-2001b" TYPE="REFERENCE">Kuwabara 2001b</LINK>). <LINK REF="REF-Jacobs-1996" TYPE="REFERENCE">Jacobs 1996</LINK> had earlier made a similar observation: patients with antibodies to ganglioside GM1 treated with IVIg recovered faster than those treated with PE.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">(3) Comparison of PE with IVIg with PE alone</HEADING>
<P>In the one trial making this comparison (<LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>), there was no significant difference in any of the outcome measures chosen for analysis in this review. No significant difference was reported for any of the outcomes measured in the trial. The mean difference (MD) in disability grade improvement was 0.20 grade more improvement in the combined treatment than the PE group. The 95% CI of the difference was -0.04 to 0.63, which included the possibility of 0.5 grade more improvement in the combined treatment group and did not fulfil the requirements for equivalence which had been predefined by the authors of that trial.</P>
<P>Adverse events were more common in the group that received PE followed by IVIg than in the group that underwent PE alone (see <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK>). In view of this and the greater cost, the use of this sequential treatment regimen does not seem justified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">(4) Comparison of IVIg added to immunoabsorption with immunoabsorption alone</HEADING>
<P>The trial that conducted this comparison used a block sequential design, which may not have adequately controlled for factors affecting outcome (<LINK REF="STD-Haupt-1996" TYPE="STUDY">Haupt 1996</LINK>). Consequently we did not think that greater improvement in disability grade after four weeks seen in the sequential treatment group was conclusive evidence of the superiority of that regimen.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">(5) Comparison of IVIg with immunoabsorption alone</HEADING>
<P>The one trial using this comparison involved 41 participants and did not show any significant difference in outcome measures, including the number of participants who improved by one disability grade or the mean disability grade improvement after 4 weeks or 12 months (<LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>). An unstated number of participants in the trial of <LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK> comparing PE with IVIg actually received PE via immunoabsorption. That trial also showed no difference in any outcome measure between IVIg and the PE/immunoabsorption group. PE and immunoabsorption are used to treat the same condition, but their effects cannot be assumed to be the same. There are differences, which depend on the immunoabsorbant column, and on the proportions of immunoglobulin G (IgG) and immunoglobulin M and other plasma proteins removed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">(6) Comparison of different doses of IVIg</HEADING>
<P>The trials comparing IVIg with PE or immunoabsorption all used the standard dose of IVIg, which is 2.0 g/kg, given as 0.4 g/kg daily for five days. In Kawasaki disease 2.0 g/kg given in 24 hours has been shown to be superior (<LINK REF="REF-Newburger-1991" TYPE="REFERENCE">Newburger 1991</LINK>). The randomised trial included in this review comparing 2.0 g/kg given in 48 hours with the standard five-day regimen in children did not show any significant differences except that early relapses were significantly more common with the shorter course (<LINK REF="STD-Korinthenberg-2005b" TYPE="STUDY">Korinthenberg 2005b</LINK>). The numbers in this trial were not large enough to exclude moderate differences between these regimens. The one trial addressing the optimal dose compared three with six days of IVIg 0.4 g/kg in 39 participants with severe GBS and contraindications to PE (<LINK REF="STD-Rapha_x00eb_l-2001" TYPE="STUDY">Raphaël 2001</LINK>). As described in the <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK> section there was a trend in favour of the larger dose. About 10% of patients relapse after IVIg and anecdotal reports exist of more favourable outcomes following a second IVIg course (<LINK REF="REF-Farcas-1997" TYPE="REFERENCE">Farcas 1997</LINK>). Furthermore there is a wide variation in the IgG levels achieved after a standard dose of IVIg in GBS, and patients with a smaller increase have a worse outcome and might benefit from a larger dose (<LINK REF="REF-Kuitwaard-2009" TYPE="REFERENCE">Kuitwaard 2009</LINK>). To resolve this important issue, a randomised trial comparing different doses of IVIg has been started in the Netherlands (<LINK REF="STD-SIDGBS-2014" TYPE="STUDY">SIDGBS 2014</LINK>). In this trial, participants predicted to have a poor prognosis by a modification of the Erasmus GBS Outcome Scale (<LINK REF="REF-van-Koningsveld-2007" TYPE="REFERENCE">van Koningsveld 2007</LINK>) one week after the start of the first IVIg dose will be randomised to receive a second dose of IVIg or placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Neuropathy disability scales</HEADING>
<P>The detection of benefit from interventions in GBS requires a scale that is simple, reproducible and sensitive to change. The scale most used has seen some modification from that proposed by <LINK REF="REF-Hughes-1978" TYPE="REFERENCE">Hughes 1978</LINK>, which is simple and reproducible but not very sensitive (<LINK REF="REF-Kleyweg-1991" TYPE="REFERENCE">Kleyweg 1991</LINK>). The incorporation of a more responsive scale would increase the power of future trials. A linear disability scale has been designed for this purpose and will be used as an additional secondary outcome in future updates of this review if the scale is incorporated into clinical trials eligible for inclusion in the review (<LINK REF="REF-van-Nes-2011" TYPE="REFERENCE">van Nes 2011</LINK>). So far we have not included measures of impairment as outcomes in the review. A linear version of the summed Medical Research Council muscle score has been developed and is a candidate secondary outcome measure which we will incorporate if it is successfully validated as being responsive (<LINK REF="REF-Vanhoutte-2012" TYPE="REFERENCE">Vanhoutte 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse events</HEADING>
<P>The possible side effects of IVIg include fever, myalgia, headache, hypotension, meningism, urticaria, eczema and, rarely, renal tubular necrosis, thromboembolic events, pancytopenia, alopecia and anaphylaxis (<LINK REF="REF-Dalakas-2004" TYPE="REFERENCE">Dalakas 2004</LINK>; <LINK REF="REF-Eijkhout-2002" TYPE="REFERENCE">Eijkhout 2002</LINK>; <LINK REF="REF-Koch-2000" TYPE="REFERENCE">Koch 2000</LINK>). <LINK REF="REF-Dalakas-2004" TYPE="REFERENCE">Dalakas 2004</LINK> estimated that such side effects occur in not more than 10% of patients. However, several series report a higher frequency. <LINK REF="REF-Bertorini-1996" TYPE="REFERENCE">Bertorini 1996</LINK> reported that 34 out of 42 (81%) patients with neuromuscular disease had complications from IVIg, which were mostly minor; the commonest was headache in 20 patients. In a series of 54 patients, 11% had aseptic meningitis (<LINK REF="REF-Sekul-1994" TYPE="REFERENCE">Sekul 1994</LINK>). Eight (6.7%) of 119 patients (287 courses) developed renal failure in another series (<LINK REF="REF-Levy-2000" TYPE="REFERENCE">Levy 2000</LINK>). The lack of uniform reporting of adverse events in the different trials makes it difficult to summarise their RRs with IVIg and PE. In all trials comparing IVIg with PE for which the information was available, there were more complications in the PE than the IVIg group (<LINK REF="STD-Bril-1996" TYPE="STUDY">Bril 1996</LINK>; <LINK REF="STD-Diener-2001" TYPE="STUDY">Diener 2001</LINK>; <LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK>; <LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK>; <LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK>). The use of IVIg carries a theoretical risk of transmission of infection, particularly by viruses and perhaps by viruses or other agents that have not yet been discovered. Concern continues to surround the transmission of the agent of variant Creutzfeld-Jacob disease, which has been transmitted by blood transfusion and may be present in the plasma fraction (<LINK REF="REF-Llewelyn-2004" TYPE="REFERENCE">Llewelyn 2004</LINK>). This may not manifest itself until many years later. Fortunately this risk of transmission of infection has not been realised and most companies that manufacture IVIg have gathered a large amount of reassuring safety data concerning their products.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Cost</HEADING>
<P>When two treatments have similar efficacy, cost becomes a significant factor in the choice of treatment. Two studies have found that the cost of PE is greater than IVIg. In the USA, <LINK REF="REF-Dawson-1997" TYPE="REFERENCE">Dawson 1997</LINK> calculated the cost of a PE course as USD 7900 and IVIg USD 6000. Based on the data from the USA and Dutch trials they calculated that the cost per responder is USD 1376 more for PE than for IVIg. When comparing 10 patients in Taiwan treated with PE and 7 treated with IVIg, <LINK REF="REF-Tsai-2007" TYPE="REFERENCE">Tsai 2007</LINK> found that the actual costs of IVIg were greater than PE, but the total hospital costs were less. Two other studies have found that the cost of IVIg is greater than PE (<LINK REF="REF-Nagpal-1999" TYPE="REFERENCE">Nagpal 1999</LINK>; <LINK REF="REF-Winters-2011" TYPE="REFERENCE">Winters 2011</LINK>). In Canada the cost of a course of PE was calculated to be USD 6204, while the cost of IVIg was USD 10,165 (<LINK REF="REF-Nagpal-1999" TYPE="REFERENCE">Nagpal 1999</LINK>). The calculation assumed the same PE and IVIg regimens as in the <LINK REF="STD-PSGBS-Study-Group-1997" TYPE="STUDY">PSGBS Study Group 1997</LINK> trial. In a study sponsored by an apheresis organisation in the USA, <LINK REF="REF-Winters-2011" TYPE="REFERENCE">Winters 2011</LINK> calculated the direct cost of a standard course of IVIg 2.0 g/kg as USD 10,330, more than twice the cost of a standard course of five PEs which was USD 4638. Costs of both PE and IVIg vary between countries and with time so that the differential cost will also vary. In practice the much greater availability of IVIg makes it the treatment of choice in many centres.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-18 18:01:04 +0100" MODIFIED_BY="Ruth  Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-18 18:01:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>In adults, there are no adequate comparisons of IVIg with placebo. Previous trials and a previous Cochrane review had shown that PE significantly hastens recovery compared with supportive care alone (<LINK REF="REF-Rapha_x00eb_l-2012" TYPE="REFERENCE">Raphaël 2012</LINK>). In this review, moderate quality evidence from randomised trials shows that IVIg commenced within two weeks from onset hastens recovery as much as PE, which is known to be more effective than supportive care alone. According to moderate quality evidence there is no difference in the frequency of adverse events, but treatment with IVIg is significantly more likely to be completed than PE. In a single trial, giving IVIg after PE did not confer significant extra benefit compared with PE alone. In children, low quality evidence suggests that IVIg hastens recovery compared with supportive care alone.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-03-03 12:42:29 +0000" MODIFIED_BY="Ruth Brassington">
<P>Randomised trials are needed to decide whether IVIg helps in mild GBS, and in disease that has lasted more than two weeks. Randomised trials also need to establish the optimal dose. Future trials would be helped by agreement on criteria for recording adverse events and the validation of recently developed potentially more sensitive outcome measures.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-06-19 10:46:32 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We particularly acknowledge the late Professor J-C Raphael who co-authored previous versions of this review. We also thank Dr Uysal for providing unpublished data from the <LINK REF="STD-G_x00fc_rses-1995" TYPE="STUDY">Gürses 1995</LINK> trial, Dr PIM Schmitz for providing unpublished data from the <LINK REF="STD-van-der-Mech_x00e9_-1992" TYPE="STUDY">van der Meché 1992</LINK> trial, Dr R Korinthenberg for providing unpublished data from the <LINK REF="STD-Korinthenberg-2005a" TYPE="STUDY">Korinthenberg 2005a</LINK> and <LINK REF="STD-Korinthenberg-2005b" TYPE="STUDY">Korinthenberg 2005b</LINK> trials, Dr N Umemoto for supplying a translation of the paper by <LINK REF="STD-Nomura-2001" TYPE="STUDY">Nomura 2001</LINK>, Dr Yueying Ju for translating the <LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK> trial and Dr Philippa Middleton of the Australasian Cochrane Centre for advice.</P>
<P>The editorial base of the Cochrane Neuromuscular Disease Group is supported by the UK Medical Research Council (MRC) Centre for Neuromuscular Diseases and a donation from Guillain-Barré &amp; Associated Inflammatory Neuropathies (gain), funded using money raised in memory of Candice Marie Roberts. The Cochrane Neuromuscular Disease Group Trials Search Co-ordinator (Angela Gunn) assisted with database searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-09-16 10:28:42 +0100" MODIFIED_BY="Ruth  Brassington">
<P>RACH has or has had consultancies with the following firms which manufacture immunoglobulin: Baxter, CSL Behring, Grifols/Talecris, LFB and Octapharma. He was the principal investigator of a randomised trial included in this review.</P>
<P>PAvD and his institution have received consultancy fees from Talecris, CSL Behring and Baxter for membership of the Scientific boards of the ICE trial in CIDP, IVIg in chronic polyneuropathy, and IVIg and ScIgG in CIDP, respectively.</P>
<P>PAvD's department has the following grants or grants pending: from Baxter to conduct a RCT comparing IVIg vs IVIg and steroids in GBS, from Sanquin to conduct a RCT investigating the effect of a second course of IVIg (SID-trial) in GBS patients with a poor prognosis, and from Talecris to conduct a prospective international study on the effect of a second course of IVIg in GBS patients with a poor prognosis.</P>
<P>AVS has no known commercial conflicts of interest. He was involved as a statistician in a randomised trial of IVIg in GBS.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="[Empty name]">
<P>Richard AC Hughes (RACH) wrote the first draft and extracted the data. All the authors extracted data, commented on and revised the subsequent drafts and updates.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-06-18 20:08:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>In the 2009 update of this review, one of the authors Professor J-C Raphael, now deceased, withdrew. We reassessed bias according to the latest Cochrane 'Risk of bias' method, inserted a 'Risk of bias' graph and deleted the previous methodological table. We have inserted a 'Summary of findings' table for the main comparison, IVIg versus PE. We selected the primary outcome for the table and the following additional outcomes: improvement by one or more disability grades after four weeks; death or disability (inability to walk without aid) after 12 months; treatment-related fluctuation; adverse events; and discontinuation of treatment. Improvement by one or more disability grades after four weeks and discontinuation of treatment were not included in the protocol for the review but improvement by one or more grades is preferred by some to mean changes of the group and discontinuation of treatment showed a very large, clinically important difference.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-09-19 09:43:28 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDIES MODIFIED="2014-06-18 20:09:10 +0100" MODIFIED_BY="Ruth  Brassington">
<INCLUDED_STUDIES MODIFIED="2014-06-18 20:09:10 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Bril-1996" MODIFIED="2012-05-08 12:28:06 +0100" MODIFIED_BY="Angela A Gunn" NAME="Bril 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-05-08 12:28:06 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K</AU>
<TI>Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>1</NO>
<PG>100-3</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:34:31 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:34:31 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8559353"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diener-2001" MODIFIED="2012-05-08 12:28:12 +0100" MODIFIED_BY="Angela A Gunn" NAME="Diener 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-08 12:28:12 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;The author provided more details in a manuscript&lt;/p&gt;" NOTES_MODIFIED="2012-05-08 12:28:12 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppen S, et al</AU>
<TI>A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune absorption in Guillain-Barré syndrome</TI>
<SO>European Neurology</SO>
<YR>2001</YR>
<VL>46</VL>
<NO>2</NO>
<PG>107-9</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:38:31 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:38:31 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11528165"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Bayoumi-2011" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" NAME="El-Bayoumi 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM</AU>
<TI>Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study</TI>
<SO>Critical Care (London, England)</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>4</NO>
<PG>R164</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:28:32 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:28:32 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="21745374"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-G_x00fc_rses-1995" MODIFIED="2012-05-08 12:28:17 +0100" MODIFIED_BY="Angela A Gunn" NAME="Gürses 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-05-08 12:28:17 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gürses N, Uysal S, Çetinkaya F, Íslek Í, Kalayci AG</AU>
<TI>Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>27</VL>
<NO>3</NO>
<PG>241-3</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:40:01 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:40:01 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8539548"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haupt-1996" MODIFIED="2014-06-18 19:55:49 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Haupt 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-06-18 19:55:27 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haupt WF, Birkmann C, van der Ven C, Pawlik G</AU>
<TI>Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome</TI>
<SO>Therapeutic Apheresis</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>3</NO>
<PG>198-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-18 19:55:39 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G</AU>
<TI>Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1996</YR>
<VL>137</VL>
<NO>2</NO>
<PG>145-9</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:41:45 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:41:45 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8782169"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-18 19:55:49 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G</AU>
<TI>Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin</TI>
<SO>Therapeutic Apheresis</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>1</NO>
<PG>55-7</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:42:54 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:42:54 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="10225782"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korinthenberg-2005a" MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Angela A Gunn" NAME="Korinthenberg 2005a" YEAR="2005">
<REFERENCE MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Korinthenberg R, Schessl J, Kirschner J, Mönting JS</AU>
<TI>Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>1</NO>
<PG>8-14</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:44:04 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:44:04 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="15995024"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-24 14:56:05 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Two trials one in mild disease of 2 g/kg in 2 days (n = 18) versus nil (n = 5) and one of severe disease with the same dose in either 2 or 5 days. Neither trial showed any significant difference.&lt;/p&gt;" NOTES_MODIFIED="2010-03-24 14:56:05 +0000" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korinthenberg RK, Schessl J, Kirschner J</AU>
<TI>Prospective multicentre study on treatment of Guillain-Barré syndrome with high-dose immunoglobulins</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>724</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Korinthenberg-2005b" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" NAME="Korinthenberg 2005b" YEAR="2005">
<REFERENCE MODIFIED="2011-08-15 15:09:46 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Korinthenberg R, Schessl J, Kirschner J, Monting JS</AU>
<TI>Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>1</NO>
<PG>8-14</PG>
<IDENTIFIERS MODIFIED="2011-08-15 14:48:24 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 14:48:24 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="15995024"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korinthenberg RK, Schessl J, Kirschner J</AU>
<TI>Prospective multicentre study on treatment of Guillain-Barré syndrome with high-dose immunoglobulins</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>724</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nomura-2001" MODIFIED="2012-05-08 12:28:43 +0100" MODIFIED_BY="Angela A Gunn" NAME="Nomura 2001" YEAR="2000">
<REFERENCE MODIFIED="2012-05-08 12:28:43 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nomura K, Hamaguchi K, Hosokawa T, Hattori T, Satou T, Mannen T, et al</AU>
<TI>A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome</TI>
<SO>Neurological Therapeutics</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>1</NO>
<PG>69-81</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:23:14 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PSGBS-Study-Group-1997" MODIFIED="2012-05-08 12:28:30 +0100" MODIFIED_BY="Angela A Gunn" NAME="PSGBS Study Group 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-05-08 12:28:30 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>PSGBS Study Group</AU>
<TI>Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9047</NO>
<PG>225-30</PG>
<IDENTIFIERS MODIFIED="2011-08-15 15:18:25 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 15:18:25 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9014908"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapha_x00eb_l-2001" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" NAME="Raphaël 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;Please can you check the details of this reference. I have looked at the electronic copy of this vol/iss but could not find the article.&lt;/p&gt;" NOTES_MODIFIED="2012-05-08 11:49:40 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raphaël JC, Harboun M, Bolgert F; Groupe Coopératif d'étude sur le SGB</AU>
<TI>Comparison of two doses of immunoglobulin for patients with GBS and contraindications to plasma exchange</TI>
<TO>Comparaison de deux posologies d'immunoglobulines (IgIV) chez les patients présentant un syndrome de Guillain-Barré (SGB) et des contre-indications aux échanges plasmatiques. Résultants de la premiere analyse intermédiare</TO>
<SO>Réanimation Urgences</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>135s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raphael J-C, Chevret S, Harboun M, Jars-Guincestre M-C; French Guillain-Barré syndrome Study Group</AU>
<TI>Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>2001</YR>
<VL>71</VL>
<NO>2</NO>
<PG>235-8</PG>
<IDENTIFIERS MODIFIED="2011-08-15 15:32:57 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 15:32:57 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11459901"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Mech_x00e9_-1992" MODIFIED="2014-06-18 20:09:10 +0100" MODIFIED_BY="Ruth  Brassington" NAME="van der Meché 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-06-18 20:09:10 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Meché FGA, Schmitz PIM; Dutch Guillain-Barré Study Group</AU>
<TI>A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>17</NO>
<PG>1123-9</PG>
<IDENTIFIERS MODIFIED="2011-08-15 15:35:53 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 15:35:53 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="1552913"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2001" MODIFIED="2012-05-08 12:28:38 +0100" MODIFIED_BY="Angela A Gunn" NAME="Wang 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-08 12:28:38 +0100" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang R, Feng A, Sun W, Wen Z</AU>
<TI>Intravenous immunoglobulin therapy in children with Guillain-Barré syndrome</TI>
<SO>Journal of Applied Clinical Pediatrics</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>4</NO>
<PG>223-4</PG>
<IDENTIFIERS MODIFIED="2011-08-15 15:46:08 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-08-15 15:46:08 +0100" MODIFIED_BY="Angela A Gunn" TYPE="DOI" VALUE="cnki:ISSN:1003-515X.0.2001-04-029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-06-18 19:56:10 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Fasanaro-1992" NAME="Fasanaro 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;not a randomised controlled trial. observational study of 26 patients treated with PE and 7 treated with IVIg who had contraindications to PE&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fasanaro AM, Pizza V, Stella L</AU>
<TI>Plasma exchange and IV immunoglobulins: new approaches to the treatment of Guillain-Barré syndrome</TI>
<SO>Acta Neurologica (Napoli)</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>4-6</NO>
<PG>369-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horstkotte-1992" NAME="Horstkotte 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horstkotte D, Kutkuhn B, Schultheiss HP, Strauer BE</AU>
<TI>Prophylactic use of human Ig-GAM-preparations in patients on mechanical ventilation undergoing plasmapheresis: results of a randomized study</TI>
<TO>Prophylaktischer Einsatz humaner Ig-GAM-Konzentrate bei Patienten mit Plasmaseparation unter Respiratortherapie: Ergebnisse einer randomisierten Studie</TO>
<SO>Intensivmedizin und Notfallmedizin</SO>
<YR>1992</YR>
<VL>29</VL>
<NO>5</NO>
<PG>227-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosokawa-1998" NAME="Hosokawa 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Not clear whether randomised or not: 15 patients with GBS or postinfectious cranial neuritis were divided into two groups 7 received IVIg and 8 PE. There was no difference in the rate of recovery of muscle strength at 1, 2, 3 or 4 weeks between the groups. I have written to the authors to ask how they allocated the patients. RH7.5.03.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosokawa T, Hamaguchi K, Tomioka R, Tsuji T, Nomura K, Ohno R, et al</AU>
<TI>Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report</TI>
<SO>Therapeutic Apheresis</SO>
<YR>1998</YR>
<VL>2</VL>
<NO>4</NO>
<PG>288-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanra-1997" NAME="Kanra 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanra G, Ozon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H</AU>
<TI>Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome</TI>
<SO>European Journal of Paediatric Neurology</SO>
<YR>1997</YR>
<VL>1</VL>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koul-2003" NAME="Koul 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koul R, Chacko A, Ahmed R, Varghese T, Javed H, Al Lamki Z</AU>
<TI>Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras</TI>
<SO>Journal of Child Neurology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>11</NO>
<PG>767-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuwabara-2001" MODIFIED="2014-06-18 19:56:10 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Kuwabara 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-06-18 19:56:10 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M</AU>
<TI>Intravenous immunoglobulin therapy for Guillain-Barré syndrome</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravasio-1995" MODIFIED="2012-05-08 12:29:09 +0100" MODIFIED_BY="[Empty name]" NAME="Ravasio 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-05-08 12:29:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;In an incidence study 36 out of 50 patients had received PE or IVIg but had not been randomised. There was a trend in favour of more recovery after three months in 20 patients who received IVIg copared with 16 who received PE as their first treatment.&lt;/p&gt;" NOTES_MODIFIED="2012-05-08 12:29:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravasio A, Pasquinelli M, Currò Dossi B, Neri W, Guidi C, Gessaroli M, et al; Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology</AU>
<TI>High dose intravenous immune globulins and plasma exchange in Guillain-Barré syndrome</TI>
<SO>Italian Journal of Neurological Sciences</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>7</NO>
<PG>487-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reisin-1996" MODIFIED="2012-05-08 12:29:13 +0100" MODIFIED_BY="Ruth Brassington" NAME="Reisin 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-05-08 12:29:13 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Not randomised. 4 children with inexcitable nerves treated with IVIg 1.9 g/kg fared no differently from 5 children treated without (historical controls)&lt;/p&gt;" NOTES_MODIFIED="2012-05-08 12:29:13 +0100" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reisin RC, Pociecha J, Rodriguez E, Massaro ME, Arroyo HA, Fejerman N</AU>
<TI>Severe Guillain-Barré syndrome in childhood treated with human immune globulin</TI>
<SO>Paediatric Neurology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>4</NO>
<PG>308-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Y_x00e9_lamos-1998" MODIFIED="2012-05-08 12:29:17 +0100" MODIFIED_BY="Ruth Brassington" NAME="Yélamos 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-05-08 12:29:17 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Not a randomised or quasi-randomised trial&lt;/p&gt;" NOTES_MODIFIED="2012-05-08 12:29:17 +0100" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yélamos AM, Vilanueva MH, Plana MO, Homs JM, Catafau JS, Martinez-Matos JA</AU>
<TI>Treatment of Guillain-Barré syndrome: immunoglobulins or plasmapheresis</TI>
<TO>Tratiamento del sindrome de Guillain-Barré: immunoglobulinas o plasmaféresis</TO>
<SO>Neurologia</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>4</NO>
<PG>166-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-06-18 19:56:25 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="MIX" ID="STD-SIDGBS-2014" MODIFIED="2014-06-18 19:56:25 +0100" MODIFIED_BY="Ruth  Brassington" NAME="SIDGBS 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-06-18 19:56:25 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Doorn PA</AU>
<TI>What's new in Guillain-Barré syndrome 2007-2008</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2009</YR>
<VL>14</VL>
<NO>2</NO>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-19 09:43:28 +0100" MODIFIED_BY="Ruth  Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-19 09:43:28 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Asbury-1990" MODIFIED="2009-11-04 12:25:59 +0000" MODIFIED_BY="Jane Batchelor" NAME="Asbury 1990" TYPE="JOURNAL_ARTICLE">
<AU>Asbury AK, Cornblath DR</AU>
<TI>Assessment of current diagnostic criteria for Guillain-Barré syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1990</YR>
<VL>27 Suppl</VL>
<PG>S21-4</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:25:59 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Bernsen-1999" MODIFIED="2014-06-18 19:56:44 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Bernsen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG</AU>
<TI>Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>2</NO>
<PG>409-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bertorini-1996" MODIFIED="2014-06-18 19:57:01 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Bertorini 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH</AU>
<TI>Complications of intravenous gammaglobulin in neuromuscular and other diseases</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>3</NO>
<PG>388-91</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:26:13 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Bick-2013" MODIFIED="2014-01-02 16:44:41 +0000" MODIFIED_BY="Richard Hughes" NAME="Bick 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bick S, Tschernatsch M, Karg A, Fuehlhuber V, Trenczek TE, Faltermeier K, et al</AU>
<TI>Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action?</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>2013</YR>
<VL>256</VL>
<NO>1-2</NO>
<PG>84-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casteels_x002d_van-Daele-1992" MODIFIED="2014-06-18 19:57:11 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Casteels-van Daele 1992" TYPE="JOURNAL_ARTICLE">
<AU>Casteels-van Daele M, Wijndaele L, Brock P, Kruger M</AU>
<TI>Aseptic meningitis associated with high dose intravenous immunoglobulin therapy</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1992</YR>
<VL>55</VL>
<NO>10</NO>
<PG>980-1</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:27:00 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Dalakas-2004" MODIFIED="2014-05-07 16:56:54 +0100" MODIFIED_BY="Ruth Brassington" NAME="Dalakas 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dalakas MC</AU>
<TI>The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile</TI>
<SO>Pharmacology &amp; Therapeutics</SO>
<YR>2004</YR>
<VL>102</VL>
<NO>3</NO>
<PG>177-93</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:25:23 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Dawson-1997" NAME="Dawson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dawson WB, Phillips LH 2nd</AU>
<TI>A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>5</NO>
<PG>377-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eijkhout-2002" MODIFIED="2014-06-18 19:57:26 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Eijkhout 2002" TYPE="BOOK_SECTION">
<AU>Eijkhout HW, van Aken WG</AU>
<TI>33 Blood, blood components, plasma and plasma products</TI>
<SO>Side Effects of Drugs Annual</SO>
<YR>2002</YR>
<EN>14th</EN>
<ED>Aronson JK</ED>
<PB>Elsevier</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farcas-1997" NAME="Farcas 1997" TYPE="JOURNAL_ARTICLE">
<AU>Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I</AU>
<TI>Efficacy of a repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9093</NO>
<PG>1747</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-Co_x002d_operative-Group-1987" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Jane Batchelor" NAME="French Co-operative Group 1987" TYPE="JOURNAL_ARTICLE">
<AU>French Co-operative Group on Plasma Exchange in Guillain-Barré Syndrome</AU>
<TI>Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids</TI>
<SO>Annals of Neurology</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>6</NO>
<PG>753-61</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:28:02 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-French-Co_x002d_operative-Group-1992" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Jane Batchelor" NAME="French Co-operative Group 1992" TYPE="JOURNAL_ARTICLE">
<AU>French Co-operative Group on Plasma Exchange in Guillain-Barré Syndrome</AU>
<TI>Plasma exchange in Guillan-Barré syndrome: one-year follow- up</TI>
<SO>Annals of Neurology</SO>
<YR>1992</YR>
<VL>32</VL>
<NO>1</NO>
<PG>94-7</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:28:31 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-French-Co_x002d_operative-Group-1997" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Jane Batchelor" NAME="French Co-operative Group 1997" TYPE="JOURNAL_ARTICLE">
<AU>French Co-operative Group on Plasma Exchange in Guillain-Barré Syndrome</AU>
<TI>Appropriate number of plasma exchanges in Guillain-Barré syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>3</NO>
<PG>298-306</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:55:37 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-GBS-Study-Group-1985" MODIFIED="2009-11-04 12:55:49 +0000" MODIFIED_BY="Jane Batchelor" NAME="GBS Study Group 1985" TYPE="JOURNAL_ARTICLE">
<AU>The Guillain-Barré Syndrome Study Group</AU>
<TI>Plasmapheresis and acute Guillain-Barré syndrome</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1096-104</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:55:49 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Greenwood-1984" MODIFIED="2009-11-04 12:28:44 +0000" MODIFIED_BY="Jane Batchelor" NAME="Greenwood 1984" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood RJ, Newsom Davis J, Hughes RA, Aslan S, Bowden AN, Chadwick DW, et al</AU>
<TI>Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>1</VL>
<NO>8382</NO>
<PG>877-9</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:28:44 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Hadden-1998" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Jane Batchelor" NAME="Hadden 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al</AU>
<TI>Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group</TI>
<SO>Annals of Neurology</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>5</NO>
<PG>780-8</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:28:56 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2009-11-04 12:56:01 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1978" MODIFIED="2009-11-04 12:30:06 +0000" MODIFIED_BY="Jane Batchelor" NAME="Hughes 1978" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM</AU>
<TI>Controlled trial of prednisolone in acute polyneuropathy</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<NO>8093</NO>
<PG>750-3</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:30:06 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2005" MODIFIED="2014-05-07 16:57:47 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hughes 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RAC, Cornblath DR</AU>
<TI>Guillain-Barré syndrome</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9497</NO>
<PG>1653-66</PG>
<IDENTIFIERS MODIFIED="2010-05-10 17:36:08 +0100" MODIFIED_BY="Angela Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007" MODIFIED="2014-06-18 19:57:41 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hughes 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA</AU>
<TI>Immunotherapy for Guillain-Barré syndrome: a systematic review</TI>
<SO>Brain</SO>
<YR>2007</YR>
<VL>130</VL>
<NO>Pt 9</NO>
<PG>2245-57</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:44:12 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2012" MODIFIED="2014-09-19 09:43:28 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hughes 2012" TYPE="COCHRANE_REVIEW">
<AU>Hughes RA, van Doorn PA</AU>
<TI>Corticosteroids for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2014-05-07 16:12:27 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-05-07 16:12:27 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001446.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Imbach-1981" MODIFIED="2009-11-04 12:30:20 +0000" MODIFIED_BY="Jane Batchelor" NAME="Imbach 1981" TYPE="JOURNAL_ARTICLE">
<AU>Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al</AU>
<TI>High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8232</NO>
<PG>1228-31</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:30:20 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Italian-Guillain_x002d_Barr_x00e9_-Group-1996" MODIFIED="2009-11-04 12:56:16 +0000" MODIFIED_BY="Jane Batchelor" NAME="Italian Guillain-Barré Group 1996" TYPE="JOURNAL_ARTICLE">
<AU>The Italian Guillain-Barré Group</AU>
<TI>The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients</TI>
<SO>Brain</SO>
<YR>1996</YR>
<VL>119</VL>
<NO>Pt 6</NO>
<PG>2053-61</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:56:16 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-1996" MODIFIED="2014-06-18 19:58:19 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Jacobs 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs BC, van Doorn PA, Schmitz P, Tio-Gillen A, Herbrink P, Visser LH, et al</AU>
<TI>Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>2</NO>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleyweg-1988" MODIFIED="2014-06-18 19:58:27 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Kleyweg 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kleyweg RP, van der Meché FGA, Meulstee J</AU>
<TI>Treatment of Guillain-Barré syndrome with high dose gammaglobulin</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38</VL>
<NO>10</NO>
<PG>1639-41</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:44:55 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Kleyweg-1991" MODIFIED="2014-06-18 19:58:39 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Kleyweg 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kleyweg RP, van der Meché FG, Schmitz PI</AU>
<TI>Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>11</NO>
<PG>1103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koch-2000" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="[Empty name]" NAME="Koch 2000" TYPE="BOOK_SECTION">
<AU>Koch C</AU>
<TI>Blood, blood components, plasma and plasma products</TI>
<SO>Meyler's Side Effects of Drugs</SO>
<YR>2000</YR>
<EN>14</EN>
<ED>Dukes MNG, Aronson JR</ED>
<PB>Elsevier</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuitwaard-2009" MODIFIED="2014-06-18 19:58:52 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Kuitwaard 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al</AU>
<TI>Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>5</NO>
<PG>597-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuwabara-2001b" MODIFIED="2014-06-18 19:59:01 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Kuwabara 2001b" TYPE="JOURNAL_ARTICLE">
<AU>Kuwabara S, Mori M, Ogawara K, Hattori T, Yuki N</AU>
<TI>Indicators of rapid clinical recovery in Guillain-Barré syndrome</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2001</YR>
<VL>70</VL>
<NO>4</NO>
<PG>560-2</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:45:11 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Levy-2000" NAME="Levy 2000" TYPE="JOURNAL_ARTICLE">
<AU>Levy JB, Pusey CD</AU>
<TI>Nephrotoxicity of intravenous immunoglobulin</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>2000</YR>
<VL>93</VL>
<NO>11</NO>
<PG>751-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Llewelyn-2004" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Jane Batchelor" NAME="Llewelyn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al</AU>
<TI>Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9407</NO>
<PG>417-21</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:45:40 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-McCluskey-1990" MODIFIED="2009-11-04 12:45:50 +0000" MODIFIED_BY="Jane Batchelor" NAME="McCluskey 1990" TYPE="JOURNAL_ARTICLE">
<AU>McCluskey DR, Boyd NA</AU>
<TI>Anaphylaxis with intravenous gammaglobulin</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8719</NO>
<PG>874</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:45:50 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Merkies-1999" MODIFIED="2014-06-18 19:59:11 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Merkies 1999" TYPE="JOURNAL_ARTICLE">
<AU>Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA</AU>
<TI>Fatigue in immune-mediated polyneuropathies</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>8</NO>
<PG>1648-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagpal-1999" MODIFIED="2009-11-04 12:46:01 +0000" MODIFIED_BY="Jane Batchelor" NAME="Nagpal 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR</AU>
<TI>Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>107-13</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:46:01 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Newburger-1991" NAME="Newburger 1991" TYPE="JOURNAL_ARTICLE">
<AU>Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al</AU>
<TI>A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<NO>23</NO>
<PG>1633-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-Consensus-Development-1986" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Jane Batchelor" NAME="NIH Consensus Development 1986" TYPE="JOURNAL_ARTICLE">
<AU>NIH Consensus Development</AU>
<TI>The utility of therapeutic plasmapheresis for neurological disorders</TI>
<SO>JAMA</SO>
<YR>1986</YR>
<VL>256</VL>
<NO>10</NO>
<PG>1333-7</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:56:30 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Osterman-1984" MODIFIED="2009-11-04 12:56:38 +0000" MODIFIED_BY="Jane Batchelor" NAME="Osterman 1984" TYPE="JOURNAL_ARTICLE">
<AU>Osterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Siden A, et al</AU>
<TI>Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>8415</NO>
<PG>1296-9</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:56:38 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Rajabally-2012" MODIFIED="2014-01-02 16:02:50 +0000" MODIFIED_BY="Richard Hughes" NAME="Rajabally 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rajabally YA, Uncini A</AU>
<TI>Outcome and its predictors in Guillain-Barre syndrome</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2012</YR>
<VL>83</VL>
<NO>7</NO>
<PG>711-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-2012" MODIFIED="2014-06-18 20:09:32 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Raphaël 2012" TYPE="COCHRANE_REVIEW">
<AU>Raphael JC, Chevret S, Hughes RA, Annane D</AU>
<TI>Plasma exchange for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2014-05-07 16:21:47 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-05-07 16:21:47 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001798.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rees-1998" MODIFIED="2014-06-18 19:59:33 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Rees 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rees JH, Thompson RD, Smeeton NC, Hughes RA</AU>
<TI>Epidemiological study of Guillain-Barré syndrome in south east England</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1998</YR>
<VL>64</VL>
<NO>1</NO>
<PG>74-7</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:53:17 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rinaldi-2013" MODIFIED="2014-05-07 16:32:55 +0100" MODIFIED_BY="Ruth Brassington" NAME="Rinaldi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Rinaldi S</AU>
<TI>Update on Guillain-Barre syndrome</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>2</NO>
<PG>99-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sejvar-2011" MODIFIED="2014-01-02 16:57:31 +0000" MODIFIED_BY="Richard Hughes" NAME="Sejvar 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al</AU>
<TI>Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data</TI>
<SO>Vaccine</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>3</NO>
<PG>599-612</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sekul-1994" NAME="Sekul 1994" TYPE="JOURNAL_ARTICLE">
<AU>Sekul EA, Cupler EJ, Dalakas MC</AU>
<TI>Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<NO>4</NO>
<PG>259-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tackenberg-2009" MODIFIED="2014-05-07 16:35:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Tackenberg 2009" TYPE="JOURNAL_ARTICLE">
<AU>Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al</AU>
<TI>Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>2009</YR>
<VL>106</VL>
<NO>12</NO>
<PG>4788-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-1993" MODIFIED="2009-11-04 12:53:32 +0000" MODIFIED_BY="Jane Batchelor" NAME="Tan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR</AU>
<TI>Acute renal failure resulting from intravenous immunoglobulin therapy</TI>
<SO>Archives of Neurology</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>2</NO>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsai-2007" MODIFIED="2009-11-04 12:53:40 +0000" MODIFIED_BY="Jane Batchelor" NAME="Tsai 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tsai CP, Wang KC, Liu CY, Sheng WY, Lee TC</AU>
<TI>Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin</TI>
<SO>Journal of Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>7</NO>
<PG>625-9</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:53:40 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-van-Koningsveld-2004" MODIFIED="2014-06-18 19:59:47 +0100" MODIFIED_BY="Ruth  Brassington" NAME="van Koningsveld 2004" TYPE="JOURNAL_ARTICLE">
<AU>van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser LH, Meulstee J, van Doorn PA; Dutch GBS Study Group</AU>
<TI>Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<PG>192-6</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:54:00 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-van-Koningsveld-2007" MODIFIED="2014-06-18 19:59:55 +0100" MODIFIED_BY="Ruth  Brassington" NAME="van Koningsveld 2007" TYPE="JOURNAL_ARTICLE">
<AU>van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC</AU>
<TI>A clinical prognostic scoring system for Guillain-Barré syndrome</TI>
<SO>Lancet Neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>7</NO>
<PG>589-94</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:54:24 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-van-Nes-2011" MODIFIED="2014-01-02 17:48:08 +0000" MODIFIED_BY="Richard Hughes" NAME="van Nes 2011" TYPE="JOURNAL_ARTICLE">
<AU>van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al</AU>
<TI>Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies</TI>
<SO>Clinical &amp; Vaccine Immunology: CVI</SO>
<YR>2011</YR>
<VL>76</VL>
<NO>4</NO>
<PG>337-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vanhoutte-2012" MODIFIED="2014-05-07 16:36:21 +0100" MODIFIED_BY="Ruth Brassington" NAME="Vanhoutte 2012" TYPE="JOURNAL_ARTICLE">
<AU>Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, et al</AU>
<TI>Modifying the Medical Research Council grading system through Rasch analyses</TI>
<SO>Brain</SO>
<YR>2012</YR>
<VL>135</VL>
<NO>Pt 5</NO>
<PG>1639-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-1985" MODIFIED="2014-06-18 20:00:04 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Vermeulen 1985" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen M, van der Meché FGA, Speelman JD, Weber A, Busch HFM</AU>
<TI>Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1985</YR>
<VL>70</VL>
<NO>3</NO>
<PG>317-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whittam-1997" MODIFIED="2009-11-04 12:54:35 +0000" MODIFIED_BY="Jane Batchelor" NAME="Whittam 1997" TYPE="JOURNAL_ARTICLE">
<AU>Whittam LR, Hay RJ, Hughes RA</AU>
<TI>Eczematous reactions to human immune globulin</TI>
<SO>British Journal of Dermatology</SO>
<YR>1997</YR>
<VL>137</VL>
<NO>3</NO>
<PG>481-2</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:54:35 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Winters-2011" MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="[Empty name]" NAME="Winters 2011" TYPE="JOURNAL_ARTICLE">
<AU>Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr</AU>
<TI>Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome</TI>
<SO>BMC Health Services Research</SO>
<YR>2011</YR>
<VL>11</VL>
<PG>101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-1999" MODIFIED="2009-11-04 12:56:57 +0000" MODIFIED_BY="Jane Batchelor" NAME="Yu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yu Z, Lennon VA</AU>
<TI>Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>3</NO>
<PG>227-8</PG>
<IDENTIFIERS MODIFIED="2009-11-04 12:56:57 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Yuki-2000" MODIFIED="2014-06-18 20:00:15 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Yuki 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, et al</AU>
<TI>Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside</TI>
<SO>Annals of Neurology</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>3</NO>
<PG>314-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yuki-2012" MODIFIED="2014-06-18 20:00:53 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Yuki 2012" TYPE="JOURNAL_ARTICLE">
<AU>Yuki N, Hartung HP</AU>
<TI>Guillain-Barré syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<NO>24</NO>
<PG>2294-304</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-18 20:02:25 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Hughes-2000" MODIFIED="2014-06-18 20:00:25 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hughes 2000" TYPE="COCHRANE_REVIEW">
<AU>Hughes R, Raphaël J, Swan A, van Doorn P</AU>
<TI>Intravenous immunoglobulin for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>unknown</NO>
<IDENTIFIERS MODIFIED="2014-03-03 16:41:27 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-03 16:41:27 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2004" MODIFIED="2014-06-18 20:00:40 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hughes 2004" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, Raphaël JC, Swan AV, van Doorn PA</AU>
<TI>Intravenous immunoglobulin for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-03-03 16:42:50 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-03 16:42:50 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002063.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2006" MODIFIED="2014-06-18 20:02:04 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hughes 2006" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, Raphaël JC, Swan AV, van Doorn PA</AU>
<TI>Intravenous immunoglobulin for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-03-03 16:44:11 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-03 16:44:11 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002063.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2010" MODIFIED="2014-06-18 20:02:14 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hughes 2010" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, Swan AV, van Doorn PA</AU>
<TI>Intravenous immunoglobulin for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2014-03-03 16:45:22 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-03 16:45:22 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002063.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2012a" MODIFIED="2014-06-18 20:02:25 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Hughes 2012a" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, Swan AV, van Doorn PA</AU>
<TI>Intravenous immunoglobulin for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2014-03-03 16:47:11 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-03-03 16:47:11 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002063.pub5"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-09-21 09:28:35 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-06-19 10:44:27 +0100" MODIFIED_BY="Ruth  Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-06-18 20:11:51 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-06-18 20:08:45 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Bril-1996">
<CHAR_METHODS>
<P>Randomised<BR/>Single centre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult<BR/>N = 50</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-18 20:08:45 +0100" MODIFIED_BY="Ruth  Brassington">
<P>IVIg 0.5 g/kg daily for 4 days versus PE 40 mL/kg to 50 mL/kg on 5 occasions over 7 to 10 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-23 16:37:17 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multiple<BR/>See text of review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-18 18:01:24 +0100" MODIFIED_BY="Ruth  Brassington"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 18:01:48 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Diener-2001">
<CHAR_METHODS>
<P>Randomised <BR/>Multicentre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults (possibly children)<BR/>N = 74</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-18 18:01:48 +0100" MODIFIED_BY="Ruth  Brassington">
<P>IVIg 0.4 g/kg daily for 5 days versus PE 40 mL/kg to 50 mL/kg on 5 occasions within 14 days versus immune absorption on 5 occasions (4000 mL on 2 occasions and then 2000 mL on 3 occasions) within 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-23 16:38:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>Proportion improved one disability grade after 4 weeks and other outcomes<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>Extensive unpublished data provided but still incomplete: SD of disability grade change has been imputed as the largest value in the other trials. There were 26 withdrawals or dropouts. See text of review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 18:02:02 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<CHAR_METHODS MODIFIED="2014-06-18 18:02:02 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised controlled trial</P>
<P>Open</P>
<P>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-24 13:06:28 +0000" MODIFIED_BY="[Empty name]">
<P>Children (age not specified) with GBS requiring artificial ventilation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-04 09:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>IVIg 0.4 g/kg daily for 5 days versus one plasma volume PE daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-04 09:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of mechanical ventilation; length of intensive care unit stay; ability to walk unaided within 4 weeks of intensive care unit discharge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-24 13:06:28 +0000" MODIFIED_BY="Ruth Brassington"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 18:02:18 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-G_x00fc_rses-1995">
<CHAR_METHODS>
<P>Quasi-randomised<BR/>Single centre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-23 16:49:21 +0100" MODIFIED_BY="Ruth Brassington">
<P>Children<BR/>N = 18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-23 16:39:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>IVIg 1 g/kg daily for 2 days versus supportive care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-23 16:39:31 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multiple<BR/>See text of review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-18 18:02:18 +0100" MODIFIED_BY="Ruth  Brassington"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 18:02:34 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Haupt-1996">
<CHAR_METHODS>
<P>Non-randomised<BR/>Single centre<BR/>Block sequential<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult and possibly children<BR/>N = 34</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>Immunoabsorption followed by IVIg 0.4 g/kg daily for 5 days versus immunoabsorption<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-23 16:39:46 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multiple<BR/>See text of review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-18 18:02:34 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Additional block of participants treated with PE alone</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 19:52:13 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Korinthenberg-2005a">
<CHAR_METHODS>
<P>Randomised<BR/>Multicentre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-18 19:52:13 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Children &lt; 18 years<BR/>Able to walk without aid<BR/>N = 21: 14 received IVIg, 7 did not (received supportive care)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIg 1.0 g/kg over 2 days versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-08 11:46:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: median (95% CI) maximal disease severity at nadir was 2 (2 to 5) or less in the IVIg and 3 (2 to 6) in the control participants (P = 0.25). Secondary: median onset of signs of improvement 4.5 (2 to 14) days in the IVIg and 30 (6 to 83) days in the controls (P = 0.001). Median time to improvement of disability grade 8 (2 to 105) days in the IVIg and 32 (6 to 83) days in the controls (P = 0.046). Median disability grade after 4 weeks 1 (0 to 3) in the IVIg and 2 (1 to 5) in the controls (P = 0.025). Minor adverse events occurred in 3 IVIg participants</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-18 18:02:40 +0100" MODIFIED_BY="Ruth  Brassington"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Korinthenberg-2005b">
<CHAR_METHODS MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>Randomised<BR/>Multicentre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington">
<P>Children &lt; 18 years<BR/>Unable to walk without aid<BR/>N = 51</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington">
<P>IVIg 1.0 g/kg daily for 2 days versus 0.4 g/kg daily for 5 days (same total dose = 2.0 g/kg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-08 11:46:16 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary: median time to regain unaided walking 19 days with the 2-day regimen and 13 days with the 5-day regimen (P = 0.94) Secondary: median time to improve 1 disability grade on an expanded version of the disability grade scale 5 days with both regimens. Median disability grade at nadir 4 (95% CI 3 to 6) in both groups. Median disability grade after 4 weeks 3 (0 to 5) days with the 2-day and 2 (0 to 6) with the 5-day regimen. Allergic reactions occurred in 18% with the 2-day and 20% with the 5-day regimen</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-08 11:46:23 +0100" MODIFIED_BY="Ruth Brassington">
<P>Early relapses occurred in 5/23 on the 2-day and 0/23 on the 5-day regimen (P = 0.049). Data for disability grade change were not available for 2 subjects in the 5-day group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 20:08:51 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Nomura-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Multicentre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult<BR/>N = 47</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-18 20:08:51 +0100" MODIFIED_BY="Ruth  Brassington">
<P>IVIg (Teijin brand) 0.4 g/kg daily for 5 days versus PE total 200 mL/kg to 250 mL/kg in up to 7 sessions over 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-23 16:40:46 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multiple<BR/>See text of review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-06 19:42:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>PE consisted of ultrafiltration, immunoabsorption or centrifugation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 20:08:52 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-PSGBS-Study-Group-1997">
<CHAR_METHODS>
<P>Randomised<BR/>International<BR/>Multicentre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult<BR/>N = 383</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-18 20:08:52 +0100" MODIFIED_BY="Ruth  Brassington">
<P>IVIg 0.4 g/kg daily for 5 days versus PE 250 mL/kg over 8 to 13 days<BR/>versus PE followed by IVIg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-23 16:41:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>Disability grade change after 4 weeks and see text of review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-08 11:46:57 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rapha_x00eb_l-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Multicentre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults who had contraindications to PE<BR/>N = 39</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIg (LFB) 0.4 g/kg/day for 3 days versus 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-08 11:46:57 +0100" MODIFIED_BY="Ruth Brassington">
<P>Time to regain ability to walk 5 metres with aid</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 20:08:55 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<CHAR_METHODS>
<P>Randomised<BR/>National<BR/>Multicentre<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults and children<BR/>N = 150</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-18 20:08:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>IVIg 0.4 g/kg daily for 5 days versus PE 200 mL/kg to 250 mL/kg over 7 to 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion improved 1 disability grade after 4 weeks and see text of review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-18 20:08:57 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Wang-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Single centre <BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children<BR/>N = 54</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-18 20:08:57 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Dexamethasone 5 to 10 mg daily for 5 or 7 days and then tailed over 7 to 10 days versus IVIg 0.2 to 0.3 g/kg daily for 5 or 6 days and dexamethasone 4 to 5 mg daily for 5 or 6 days and then tailed over 7 days versus PE 500 mL to 1500 mL over 5 to 10 days and dexamethasone 5 mg daily for 5 or 6 days and then tailed over 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-23 16:42:14 +0100" MODIFIED_BY="Ruth Brassington">
<P>Time to start of recovery, time to partial recovery or improvement by 1 muscle strength grade, or time to complete recovery of cranial and respiratory nerves and 2 grades of improvement in muscle strength</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="[Empty name]">
<P>Mean (SD) time to complete recovery of cranial and respiratory nerves and 2 grades of improvement in muscle strength was 17.1 (6.1) days in IVIg, 22.9 (6.7) in PE and 24.8 (12.5) in the dexamethasone alone group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CI: confidence interval<BR/>GBS: Guillain-Barré syndrome<BR/>IVIg: intravenous immunoglobulin<BR/>NINCDS: National Institute of Neurological and Communicative Disorders and Stroke<BR/>PE: plasma exchange<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-18 20:09:01 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-06-18 20:08:59 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Fasanaro-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 20:08:59 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Not a RCT. Retrospective study of 26 patients treated with PE and 7 treated with IVIg who had contraindications to PE. IVIg-treated patients recovered to unaided walking in a mean (SD) of 15 (7) days compared with 56 (69) days, but this excluded 1 patient who died in the IVIg group and 5 who died in the PE group. The groups were not comparable at the start of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 20:09:01 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Horstkotte-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 20:09:01 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Not a RCT. A retrospective study of using IVIg (including IgG, IgA and IgM) to prevent sepsis after PE in 28 patients, 12 of whom had GBS. Among 14 patients treated without IVIg there were 4 deaths and 9 had septicaemia; in 14 treated with IVIg, 1 died and 3 had septicaemias</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-07 10:15:50 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Hosokawa-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-07 10:15:50 +0000" MODIFIED_BY="Ruth Brassington">
<P>Unclear whether a randomised trial or not: 15 participants with GBS or postinfectious cranial neuritis were divided into two groups: 7 received IVIg and 8 underwent PE. There was no difference between the groups in the rate of recovery of muscle strength at 1, 2, 3 or 4 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Kanra-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a RCT, but a retrospective study. Twenty-four children in Canada received IVIg 1 g/kg daily for 2 days and 23 in Turkey 0.4 g/kg daily for 5 days. Twenty-eight more patients in Turkey received no IVIg and had supportive care only. The mean time to recover 1 grade was 17 days in the Canadian IVIg group, 21 days in the Turkish IVIg group and significantly longer, 62 days P &lt; 0.01, in the Turkish no IVIg group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-08 11:48:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koul-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-08 11:48:09 +0100" MODIFIED_BY="[Empty name]">
<P>Not a RCT. A prospective study of 42 children all treated with IVIg. 7 patients required ventilation. There were no deaths</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-08 11:48:18 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Kuwabara-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-08 11:48:18 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a RCT. 86 consecutive GBS patients included, 24 with anti-ganglioside GM1 antibodies: 6 of 10 treated with IVIg recovered 2 or more GBS disability grades in 1 month compared with 3 of 14 treated with PE (P = 0.03)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-08 11:48:24 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Ravasio-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-08 11:48:24 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-07 14:37:28 +0100" MODIFIED_BY="Richard Hughes" STUDY_ID="STD-Reisin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-07 14:37:28 +0100" MODIFIED_BY="Richard Hughes">
<P>Not a RCT, but a retrospective study. 4 children with unexcitable nerves treated with IVIg 1.9 g/kg fared no differently from 5 children treated without (historical controls). The time to reach unaided walking was 219 days in those treated with IVIg and 156 days in those not so treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-08 11:48:36 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Y_x00e9_lamos-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-08 11:48:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not stated whether a randomised trial or not, but the unequal numbers strongly suggest that it was not. 17 adult participants were treated with IVIg and 7 with PE. The groups were similar before starting treatment. The IVIg participants recovered 1 grade significantly faster than the PE participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>GBS: Guillain-Barré syndrome<BR/>Ig: immunoglobulin<BR/>IVIg: intravenous immunoglobulin<BR/>PE: plasma exchange<BR/>RCT: randomised controlled trial<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-06-19 10:44:27 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-06-19 10:44:27 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-SIDGBS-2014">
<CHAR_STUDY_NAME MODIFIED="2012-04-16 22:00:24 +0100" MODIFIED_BY="Richard Hughes">
<P>SID-GBS trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-04-04 09:12:36 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel group randomised placebo controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-04-18 14:13:08 +0100" MODIFIED_BY="[Empty name]">
<P>People with GBS who have a poor prognosis as based on the mEGOS score one week after starting their first IVIg course</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-18 14:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>Second course of IVIg 0.4 g/kg for 5 days or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-19 10:44:27 +0100" MODIFIED_BY="Ruth  Brassington">
<P>-</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-10-11 10:29:48 +0100" MODIFIED_BY="Richard Hughes">
<P>2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-10-11 10:30:30 +0100" MODIFIED_BY="Richard Hughes">
<P>Professor PA van Doorn</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-04-04 09:12:36 +0100" MODIFIED_BY="[Empty name]">
<P>In progress</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>GBS: Guillain-Barré syndrome<BR/>IVIg: intravenous immunoglobulin<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-06-18 20:11:51 +0100" MODIFIED_BY="Ruth  Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-06-18 18:02:24 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>"Patients were randomly allocated to either PE or IVIg". Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 10:27:54 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>&#8220;The randomisation procedure was performed in a stepwise manner using a computer revealing the treatment code only for the patient being randomized for the moment&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-24 13:17:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Done by computer-generated random tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-18 18:02:24 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>&#8220;Chosen according to the hospital admission sequence&#8221;. Alternate allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:14:21 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>&#8220;Assigned in consecutive blocks&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-06 19:40:35 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>"21 children were randomized." Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-06 19:41:30 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>Randomized, controlled study. Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-23 16:40:53 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Randomized. Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:46:46 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>Randomisation was by computer generation of a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:36:20 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>"Randomisation was performed in a centralised manner using a permuted block algorithm with stratification by study centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:51:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:49:48 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>"Randomization was stratified only according to centre with a block size of 6 not known to the investigators"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-06-18 18:02:27 +0100" MODIFIED_BY="Ruth  Brassington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>"Patients were randomly allocated to either PE or IVIg". Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 10:27:56 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>&#8220;The randomisation procedure was performed in a stepwise manner using a computer revealing the treatment code only for the patient being randomized for the moment&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-24 13:17:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-18 18:02:27 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>&#8220;Chosen according to the hospital admission sequence". Alternate allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>"Assigned in consecutive blocks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-06 19:40:36 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>"21 children were randomized." Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-06 19:41:29 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>Randomized, controlled study. Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-23 16:40:58 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Randomized. Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:46:44 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>Each centre was given a set of sealed, sequentially numbered randomisation envelopes, which had been prepared by the trial statistician. At randomisation, the envelope was opened to reveal the assigned treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:36:12 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>"Randomisation codes were given to the investigators by telephone"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:51:16 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 10:27:56 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>"Telephone randomisation service"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-05-08 11:47:22 +0100" MODIFIED_BY="Angela A Gunn" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes except death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-24 16:09:10 +0000" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:04:23 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>Reporting of death unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-04 09:12:35 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>Open randomised controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 20:55:20 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>Blinding would not have biased assessment of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-04 09:12:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Although decisions about removal from ventilation were made independently, no attempt was made to mask whether participants had received PE or IVIg</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-04-04 09:12:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Although decisions about removal from ventilation were made independently, no attempt was made to mask whether participants had received PE or IVIg. This would not have affected the assessment of death and in any case there were no deaths</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 21:10:10 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:09:32 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>Lack of blinding unlikely to affect reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 21:14:40 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:15:03 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>Lack of blinding unlikely to have affected assessment of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-04 13:58:21 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>Open study. No placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:19:12 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>Lack of blinding unlikely to affect reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-04 13:59:36 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>2 g/kg body weight IVIg over 2 days (1 g/kg body weight per day) versus 2 g/kg body weight IVIg over 5 days (0.4 g/kg body weight per day). No mention of placebo or blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-24 14:52:55 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>Knowledge of allocation unlikely to have affected reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 21:40:36 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:40:28 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Lack of blinding unlikely to have affected reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-08 11:46:42 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>Open but 4 weeks after randomisation, the disability and arm grades and vital capacity were assessed by an examiner who had no knowledge of the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:44:34 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>Reporting of death unlikely to have been biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-08 11:47:22 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>"The patients, investigators, and caregivers were blinded to treatment assignment until completion of the final analyses. IVIg was given at a dose of 0.4 g/kg body weight/day as a 12 hour infusion for 3 or 6 consecutive days. Double blinding was ensured by giving intravenous infusions of a placebo (3.8% albumin) from the 4th to the 6th day to the patients assigned to 3 days of IVIg therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-05-08 11:47:19 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>"The patients, investigators, and caregivers were blinded to treatment assignment until completion of the final analyses. IVIg was given at a dose of 0.4 g/kg body weight/day as a 12 hour infusion for 3 or 6 consecutive days. Double blinding was ensured by giving intravenous infusions of a placebo (3.8% albumin) from the 4th to the 6th day to the patients assigned to 3 days of IVIg therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 21:51:21 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:51:46 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 21:49:35 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>"Open study. During follow-up one of the study coordinators evaluated every patient once and the scores were compared with those of the individual investigators"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 21:48:08 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>Reporting of death unlikely to be biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-06-18 20:11:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes except death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-18 20:11:47 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>6 PE and 0 IVIg excluded because of protocol violations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:05:18 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>Reporting of death likely to have been complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>Of 23 randomised to IVIg, 2 were withdrawn before treatment and 4 did not complete. Of 26 randomised to PE, 0 were withdrawn before treatment and 9 did not complete. Of 25 randomised to immunoabsorption, 7 were withdrawn before treatment and 4 did not complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>Blinding would not have biased assessment of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-24 13:17:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Follow-up complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-01-24 13:17:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>No deaths</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-18 20:08:47 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>Complete unpublished data were obtained from the authors for the 4-week disability grade change</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:09:37 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>Lack of blinding unlikely to affect reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-28 21:15:29 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>&#8220;The statistical evaluation of all 45 patients is reported"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:15:26 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>&#8220;The statistical evaluation of all 45 patients is reported"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-28 21:19:37 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>100% assessment at 4 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:19:41 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>100% assessment at 4 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-08 11:46:27 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>4 week assessments were available for all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-05-08 11:46:29 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>4 week assessments were available for all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-08 14:28:20 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Authors supplied unpublished data for outcomes at 4 weeks for all treated participants and these data were complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:42:08 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Lack of blinding unlikely to have affected reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-28 21:44:56 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>4 week data were complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:45:24 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>Reporting of death unlikely to have been biased</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-08 11:47:17 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>2 of 21 in the 3-day group and 0 of 18 in the 6-day group did not provide data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-05-08 11:47:15 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>2 of 21 in the 3-day group and 0 of 18 in the 6-day group did not provide data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-28 21:51:48 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:51:50 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-28 21:48:57 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>146/147 participants followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-28 21:49:08 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>146/147 participants followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-06-18 20:11:51 +0100" MODIFIED_BY="Ruth  Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-18 20:11:51 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>6 were subsequently excluded from further analysis as a result of protocol violations; all were in the PE-treated group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:33:41 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>All specified outcomes specified reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-18 18:02:13 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>All specified outcomes fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-18 20:08:48 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>Complete unpublished data were obtained from the authors for the 4-week disability grade change. All specified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:35:20 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>All specified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:35:35 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>All specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:35:48 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>All specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:36:14 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Authors supplied unpublished data for outcomes at 4 weeks for all treated participants and these data were complete.All specified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:36:35 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>All specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:36:49 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>All specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:52:51 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Description inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:37:02 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>All specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 20:56:33 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>Planned sample size was 279 but trial was stopped because of changes in referral practice which made continuation hopeless</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-04 09:12:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Number of participants who did not receive full treatment unknown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:20:04 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>Despite 50:50 randomisation 14 received IVIg and 7 none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:46:34 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>4 week assessments were available for all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-04 14:10:53 +0100" MODIFIED_BY="Richard Hughes" RESULT="NO" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>Trial sponsored by one drug company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Dexamethasone 4 to 5 mg was injected before each IVIg infusion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-06-07 14:35:05 +0100" MODIFIED_BY="Richard Hughes" NO="7">
<NAME>Diagnostic criteria</NAME>
<DESCRIPTION>
<P>Were the diagnostic criteria stipulated and appropriate?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:06:23 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>NINCDS criteria for GBS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 20:54:11 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>Modified from Asbury 1978</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Standard diagnostic criteria, requirement for mechanical ventilation and &lt; 14 days of muscle weakness before randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-07 14:35:05 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>Defined criteria resembling <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-03 15:19:01 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>Criteria of Asbury and Cornblath 1990</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:46:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>Children classified as having GBS based on <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:52:56 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>Criteria of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:41:07 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>NINCDS criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:46:49 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>Diagnosed by a consultant neurologist to conform with the <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK> criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:47:03 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>
<LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK> criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:50:52 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Specified diagnostic criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:47:35 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>
<LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK> criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela A Gunn" NO="8">
<NAME>Baseline differences</NAME>
<DESCRIPTION>
<P>Were differences between groups at baseline taken into account adequately?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:53:55 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Bril-1996">
<DESCRIPTION>
<P>No significant differences in age, gender or severity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:55:30 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Diener-2001">
<DESCRIPTION>
<P>Not described in published paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-24 13:17:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Bayoumi-2011">
<DESCRIPTION>
<P>Done by computer-generated random tables: groups well balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-G_x00fc_rses-1995">
<DESCRIPTION>
<P>Small (total 18 participants) trial but unpublished data show that the two groups had similar age and severity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:13:39 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Haupt-1996">
<DESCRIPTION>
<P>No significant differences in age or disability on admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:20:25 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005a">
<DESCRIPTION>
<P>No significant differences in age, time from onset to randomisation or disability at entry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 14:52:56 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Korinthenberg-2005b">
<DESCRIPTION>
<P>No significant differences in age, time since onset or disability grade at entry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-04 09:12:36 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-Nomura-2001">
<DESCRIPTION>
<P>PE participants slightly older but disability at entry similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:46:53 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-PSGBS-Study-Group-1997">
<DESCRIPTION>
<P>At randomisation, the three treatment groups were evenly matched for distributions of age, sex, severity of disability, delay from onset, and features known, or suspected, to be related to prognosis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 11:47:28 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Rapha_x00eb_l-2001">
<DESCRIPTION>
<P>Baseline characteristics were similar in the two groups except that the proportion of ventilated participants was slightly higher in the 3-day group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:52:33 +0100" MODIFIED_BY="Richard Hughes" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 21:48:24 +0100" MODIFIED_BY="Richard Hughes" RESULT="YES" STUDY_ID="STD-van-der-Mech_x00e9_-1992">
<DESCRIPTION>
<P>Age, disability, disease duration and amplitude of compound muscle action potential were not significantly different between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-06-18 18:03:40 +0100" MODIFIED_BY="Ruth  Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-06-18 18:03:40 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-01-24 15:20:03 +0000" MODIFIED_BY="Grade Profiler">IVIg versus PE for Guillain-Barré syndrome</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>IVIg versus PE for Guillain-Barré syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with Guillain-Barré syndrome<BR/>
<B>Settings: </B>Hospital<BR/>
<B>Intervention:</B> IVIg versus PE<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PE</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>IVIg</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in disability grade 4 weeks after randomisation</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change in disability grade 4 weeks after randomisation in the control groups was<BR/>
<B>-0.86 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change in disability grade 4 weeks after randomisation in the intervention groups was<BR/>
<B>0.02 lower</B>
<BR/>(0.25 lower to 0.2 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>536<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>The disability scale ranges from 0 normal to 6 dead. Improvement is recorded as negative change. Narrow 95% CI excludes clinically important difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number improved by 1 or more disability grades after 4 weeks</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>562 per 1000</B>
<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>607 per 1000</B>
<BR/>(528 to 691)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.08 </B>
<BR/>(0.94 to 1.23)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>567<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Dead or disabled after 12 months (48 weeks)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>163 per 1000</B>
<BR/>(92 to 287)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.55 to 1.72)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>243<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Relapse or treatment-related fluctuation</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>60 per 1000</B>
<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
<BR/>(25 to 113)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.89 </B>
<BR/>(0.42 to 1.89)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>445<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Participants in whom treatment was discontinued</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>128 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(6 to 46)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.14 </B>
<BR/>(0.05 to 0.36)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>498<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>IVig significantly more likely to be completed than PE</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of participants with adverse events attributed to treatment</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>151 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>127 per 1000</B>
<BR/>(82 to 196)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.84 </B>
<BR/>(0.54 to 1.3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>388<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>IVIg:</B> intravenous immunoglobulin; <B>PE:</B> plasma exchange</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Trials were not blinded.<BR/>
<SUP>2</SUP> Mean risk in control groups.<BR/>
<SUP>3</SUP> 95% CI does not exclude 50% increase.<BR/>
<SUP>4</SUP> 95% CI excludes risk ratio &gt; 0.5.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-10-11 10:12:57 +0100" MODIFIED_BY="Richard Hughes"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-06-06 11:41:06 +0100" MODIFIED_BY="Richard Hughes">
<COMPARISON ID="CMP-001" MODIFIED="2012-04-04 14:36:50 +0100" MODIFIED_BY="Richard Hughes" NO="1">
<NAME>IVIg versus no treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2012-04-04 14:36:50 +0100" MODIFIED_BY="Richard Hughes" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.9578181562359473" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in disability grade 4 weeks after randomisation</NAME>
<GROUP_LABEL_1>Favours IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.273690326481723" CI_START="-2.566309673518277" EFFECT_SIZE="-1.42" ESTIMABLE="YES" MEAN_1="-0.71" MEAN_2="0.71" ORDER="18411" SD_1="0.99" SD_2="1.38" SE="0.5848626212319314" STUDY_ID="STD-Korinthenberg-2005a" TOTAL_1="14" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-05-01 11:18:27 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>IVIg versus PE</NAME>
<CONT_OUTCOME CHI2="6.816629385852586" CI_END="0.19939918330190645" CI_START="-0.2482846780000513" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.024442747349072428" ESTIMABLE="YES" I2="41.319972473467516" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2012-04-04 14:37:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14590182054053336" P_Q="1.0" P_Z="0.8305305743259479" Q="0.0" RANDOM="NO" SCALE="1.201416250163911" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="273" TOTAL_2="263" UNITS="" WEIGHT="100.0" Z="0.21402113691599517">
<NAME>Change in disability grade 4 weeks after randomisation</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.061590012405578154" CI_START="-0.9184099875944218" EFFECT_SIZE="-0.49" ESTIMABLE="YES" MEAN_1="-0.86" MEAN_2="-0.37" ORDER="1" SD_1="1.32" SD_2="1.33" SE="0.21858054075159805" STUDY_ID="STD-van-der-Mech_x00e9_-1992" TOTAL_1="74" TOTAL_2="73" WEIGHT="27.30006693436719"/>
<CONT_DATA CI_END="0.4218577291048074" CI_START="-0.22185772910480744" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.9" ORDER="2" SD_1="1.3" SD_2="1.3" SE="0.16421614460448258" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="130" TOTAL_2="121" WEIGHT="48.367651477464776"/>
<CONT_DATA CI_END="0.9858585144878516" CI_START="-0.5858585144878516" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.2" ORDER="18412" SD_1="1.32" SD_2="1.5" SE="0.40095558933052" STUDY_ID="STD-Bril-1996" TOTAL_1="26" TOTAL_2="24" WEIGHT="8.11323695324507"/>
<CONT_DATA CI_END="0.9638592281759057" CI_START="-0.7638592281759056" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-1.3" ORDER="18413" SD_1="1.32" SD_2="1.5" SE="0.4407526031038922" STUDY_ID="STD-Diener-2001" TOTAL_1="20" TOTAL_2="21" WEIGHT="6.714241098106663"/>
<CONT_DATA CI_END="1.126055585451903" CI_START="-0.3260555854519033" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.4" ORDER="18414" SD_1="1.0" SD_2="1.5" SE="0.37044333017286896" STUDY_ID="STD-Nomura-2001" TOTAL_1="23" TOTAL_2="24" WEIGHT="9.504803536816311"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.012929063520794" CI_END="1.2315695011358734" CI_START="0.9393744518747217" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0755951492430298" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="154" I2="28.70311456580193" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.09045892539809758" LOG_CI_START="-0.027161255479904944" LOG_EFFECT_SIZE="0.031648834959096324" METHOD="MH" MODIFIED="2012-05-01 11:18:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21968061620582713" P_Q="1.0" P_Z="0.2915347630545959" Q="0.0" RANDOM="NO" SCALE="2.95" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="293" TOTAL_2="274" WEIGHT="99.99999999999999" Z="1.0547607767551401">
<NAME>Number improved by 1 or more disability grades after 4 weeks</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVIg</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.259847907709568" CI_START="1.047978242662754" EFFECT_SIZE="1.538918918918919" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="25" LOG_CI_END="0.3540792112424589" LOG_CI_START="0.020352266245423828" LOG_EFFECT_SIZE="0.18721573874394132" ORDER="1" O_E="0.0" SE="0.19603285946627882" STUDY_ID="STD-van-der-Mech_x00e9_-1992" TOTAL_1="74" TOTAL_2="73" VAR="0.038428881990525826" WEIGHT="15.856824415902746"/>
<DICH_DATA CI_END="1.7746646883016801" CI_START="0.723172072555732" EFFECT_SIZE="1.132867132867133" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.24911630793939368" LOG_CI_START="-0.14075835378425539" LOG_EFFECT_SIZE="0.054178977077569156" ORDER="2" O_E="0.0" SE="0.22901430620717222" STUDY_ID="STD-Bril-1996" TOTAL_1="26" TOTAL_2="18" VAR="0.05244755244755245" WEIGHT="8.189835529402743"/>
<DICH_DATA CI_END="1.1889496018052694" CI_START="0.7708848365198069" EFFECT_SIZE="0.9573626373626374" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="70" LOG_CI_END="0.07516344576944092" LOG_CI_START="-0.11301049691619107" LOG_EFFECT_SIZE="-0.01892352557337505" ORDER="3" O_E="0.0" SE="0.11053430540957918" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="130" TOTAL_2="121" VAR="0.012217832672378123" WEIGHT="45.680357534517285"/>
<DICH_DATA CI_END="1.586373537439329" CI_START="0.7907343197522133" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.2004054567192266" LOG_CI_START="-0.10196941137886331" LOG_EFFECT_SIZE="0.04921802267018165" ORDER="4" O_E="0.0" SE="0.17761649430055484" STUDY_ID="STD-Diener-2001" TOTAL_1="20" TOTAL_2="21" VAR="0.03154761904761903" WEIGHT="9.219327049984326"/>
<DICH_DATA CI_END="1.4821132674226716" CI_START="0.5916873591408492" EFFECT_SIZE="0.9364548494983278" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.17088139496376953" LOG_CI_START="-0.22790770892819032" LOG_EFFECT_SIZE="-0.028513156982210408" ORDER="5" O_E="0.0" SE="0.23425069366403833" STUDY_ID="STD-Nomura-2001" TOTAL_1="23" TOTAL_2="20" VAR="0.05487338748208313" WEIGHT="8.76121940354712"/>
<DICH_DATA CI_END="1.1252858790084228" CI_START="0.7935983350176882" EFFECT_SIZE="0.945" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.05126286902838782" LOG_CI_START="-0.10039925200986191" LOG_EFFECT_SIZE="-0.024568191490737076" MODIFIED="2011-06-27 23:24:50 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.0890870806374748" STUDY_ID="STD-El_x002d_Bayoumi-2011" TOTAL_1="20" TOTAL_2="21" VAR="0.007936507936507936" WEIGHT="12.292436066645767"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9721206686744837" CI_END="1.9458678521383974" CI_START="0.309481238178162" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7760216441639188" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.28911334310817166" LOG_CI_START="-0.5093656742777062" LOG_EFFECT_SIZE="-0.11012616558476725" METHOD="MH" MODIFIED="2011-06-27 23:25:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8079975075850004" P_Q="1.0" P_Z="0.5887583854345709" Q="0.0" RANDOM="NO" SCALE="103.3093891948769" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="307" WEIGHT="100.00000000000001" Z="0.5406361685202016">
<NAME>Death</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.321895291107682" CI_START="0.04571470945917013" EFFECT_SIZE="0.49324324324324326" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.726066325506333" LOG_CI_START="-1.3399440360553359" LOG_EFFECT_SIZE="-0.3069388552745015" ORDER="1" O_E="0.0" SE="1.2135847132975515" STUDY_ID="STD-van-der-Mech_x00e9_-1992" TOTAL_1="74" TOTAL_2="73" VAR="1.4727878563495" WEIGHT="19.988061273645613"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Bril-1996" TOTAL_1="26" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.5654251726418997" CI_START="0.3498929578821961" EFFECT_SIZE="1.116923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5521113263680086" LOG_CI_START="-0.45606479825353224" LOG_EFFECT_SIZE="0.048023264057238134" ORDER="3" O_E="0.0" SE="0.5922076461549967" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="130" TOTAL_2="121" VAR="0.3507098961644417" WEIGHT="51.4121690184354"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="4" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Diener-2001" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="14.01388715688031"/>
<DICH_DATA CI_END="8.112670492455225" CI_START="0.014861107907323728" EFFECT_SIZE="0.3472222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9091638368536604" LOG_CI_START="-1.8279488123721221" LOG_EFFECT_SIZE="-0.45939248775923086" ORDER="5" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Nomura-2001" TOTAL_1="23" TOTAL_2="24" VAR="2.585" WEIGHT="14.58588255103869"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-27 23:25:20 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2001" TOTAL_1="20" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-27 23:25:43 +0100" MODIFIED_BY="[Empty name]" ORDER="18421" O_E="0.0" SE="0.0" STUDY_ID="STD-El_x002d_Bayoumi-2011" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7221893869614007" CI_START="0.5539630032553702" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9767441860465116" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.23608090855182132" LOG_CI_START="-0.2565192389151935" LOG_EFFECT_SIZE="-0.010219165181686082" METHOD="MH" MODIFIED="2009-08-12 15:16:06 +0100" MODIFIED_BY="Richard Hughes" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9351872309653753" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="114" WEIGHT="99.99999999999999" Z="0.0813202992778707">
<NAME>Dead or disabled after 12 months (48 weeks)</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7221893869614004" CI_START="0.5539630032553702" EFFECT_SIZE="0.9767441860465116" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.23608090855182126" LOG_CI_START="-0.2565192389151935" LOG_EFFECT_SIZE="-0.010219165181686082" ORDER="1" O_E="0.0" SE="0.2893557650321806" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="129" TOTAL_2="114" VAR="0.08372675875735851" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2807254845255656" CI_END="1.8877840052092139" CI_START="0.41763962598826065" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.887926464231243" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="21.91925497832645" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.27595230208491994" LOG_CI_START="-0.3791983018362606" LOG_EFFECT_SIZE="-0.051622999875670324" METHOD="MH" MODIFIED="2012-01-24 16:50:46 +0000" MODIFIED_BY="Richard Hughes" NO="5" P_CHI2="0.2577642944536903" P_Q="1.0" P_Z="0.7574180104847903" Q="0.0" RANDOM="NO" SCALE="11.0906526009438" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="227" TOTAL_2="218" WEIGHT="100.0" Z="0.30887316572603557">
<NAME>Relapse or treatment-related fluctuation</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6038066251171994" CI_START="0.4800630440726727" EFFECT_SIZE="1.3153153153153154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5567614793387502" LOG_CI_START="-0.3187017253431908" LOG_EFFECT_SIZE="0.1190298769977797" ORDER="1" O_E="0.0" SE="0.5142514200429269" STUDY_ID="STD-van-der-Mech_x00e9_-1992" TOTAL_1="74" TOTAL_2="73" VAR="0.26445452301616684" WEIGHT="45.44764980792288"/>
<DICH_DATA CI_END="1.7716397964784394" CI_START="0.15967337731924736" EFFECT_SIZE="0.5318681318681319" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24837542731201268" LOG_CI_START="-0.7967674886653751" LOG_EFFECT_SIZE="-0.27419603067668114" ORDER="2" O_E="0.0" SE="0.6139221223859894" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="130" TOTAL_2="121" VAR="0.3769003723549178" WEIGHT="54.55235019207713"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Nomura-2001" TOTAL_1="23" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.949327638071381" CI_END="0.3615528380545297" CI_START="0.05186162563878662" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13693326088217161" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="31" I2="32.18793415207554" I2_Q="100.0" ID="CMP-002.06" LOG_CI_END="-0.44182822506750097" LOG_CI_START="-1.2851538740902047" LOG_EFFECT_SIZE="-0.8634910495788527" METHOD="MH" MODIFIED="2012-01-24 16:50:58 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.22885570795767585" P_Q="0.0" P_Z="5.978435715576703E-5" Q="2.0091604866398964E-31" RANDOM="NO" SCALE="631.7692394662271" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="242" WEIGHT="100.0" Z="4.013660346056141">
<NAME>Patients in whom treatment was discontinued</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6544892362956143" CI_START="0.0023798982342228252" EFFECT_SIZE="0.039466666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.1840974914445602" LOG_CI_START="-2.6234416132209626" LOG_EFFECT_SIZE="-1.4037695523327616" ORDER="1" O_E="0.0" SE="1.4328828120796038" STUDY_ID="STD-van-der-Mech_x00e9_-1992" TOTAL_1="74" TOTAL_2="73" VAR="2.0531531531531533" WEIGHT="39.07066318089509"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Bril-1996" TOTAL_1="26" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.5134568580163174" CI_START="0.04686812465465935" EFFECT_SIZE="0.15512820512820513" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2894960410882554" LOG_CI_START="-1.3291224236598052" LOG_EFFECT_SIZE="-0.8093092323740303" ORDER="3" O_E="0.0" SE="0.6106816833561195" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="130" TOTAL_2="121" VAR="0.37293211838666385" WEIGHT="57.89058135309804"/>
<DICH_DATA CI_END="15.716706127790523" CI_START="0.06927958517860539" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1963615327710861" LOG_CI_START="-1.1593947213830598" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="4" O_E="0.0" SE="1.3837828848716724" STUDY_ID="STD-Nomura-2001" TOTAL_1="23" TOTAL_2="24" VAR="1.914855072463768" WEIGHT="3.0387554660068643"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7976806644605337" CI_START="0.11913881033695825" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30827702702702703" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.09817093498884608" LOG_CI_START="-0.9239467408720065" LOG_EFFECT_SIZE="-0.5110588379304263" METHOD="MH" MODIFIED="2012-01-24 16:51:07 +0000" MODIFIED_BY="Richard Hughes" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.015267201109826788" Q="0.0" RANDOM="NO" SCALE="11.17451716980626" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="73" WEIGHT="100.0" Z="2.4259778724160226">
<NAME>Multiple complications</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7976806644605337" CI_START="0.11913881033695825" EFFECT_SIZE="0.30827702702702703" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.09817093498884608" LOG_CI_START="-0.9239467408720065" LOG_EFFECT_SIZE="-0.5110588379304263" ORDER="1" O_E="0.0" SE="0.4850647960319324" STUDY_ID="STD-van-der-Mech_x00e9_-1992" TOTAL_1="74" TOTAL_2="73" VAR="0.2352878563495002" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.46943628201000887" CI_END="1.3034573112360193" CI_START="0.5354250881919442" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8354063357570255" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.11509681241403637" LOG_CI_START="-0.2713012831153702" LOG_EFFECT_SIZE="-0.07810223535066695" METHOD="MH" MODIFIED="2012-01-24 16:52:15 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7907939005422093" P_Q="1.0" P_Z="0.4281677870191831" Q="0.0" RANDOM="NO" SCALE="5.881110146390666" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="196" TOTAL_2="192" WEIGHT="100.00000000000001" Z="0.7923308637929266">
<NAME>Number of patients with adverse events attributed to treatment</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9536776530916666" CI_START="0.24943285283597377" EFFECT_SIZE="0.698076923076923" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.29085290890577364" LOG_CI_START="-0.603046346103147" LOG_EFFECT_SIZE="-0.15609671859868665" ORDER="1" O_E="0.0" SE="0.5250808472649157" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="130" TOTAL_2="121" VAR="0.27570989616444164" WEIGHT="29.302071852420877"/>
<DICH_DATA CI_END="2.015909026103669" CI_START="0.2755749965491528" EFFECT_SIZE="0.7453416149068323" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3044709293842757" LOG_CI_START="-0.5597601893527255" LOG_EFFECT_SIZE="-0.1276446299842249" ORDER="2" O_E="0.0" SE="0.5076536371591471" STUDY_ID="STD-Nomura-2001" TOTAL_1="23" TOTAL_2="24" VAR="0.257712215320911" WEIGHT="24.225164190429215"/>
<DICH_DATA CI_END="1.644372938733827" CI_START="0.5709487462400546" EFFECT_SIZE="0.968944099378882" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.21600032103018216" LOG_CI_START="-0.24340287638495836" LOG_EFFECT_SIZE="-0.01370127767738809" ORDER="3" O_E="0.0" SE="0.26985571224415666" STUDY_ID="STD-Diener-2001" TOTAL_1="23" TOTAL_2="26" VAR="0.07282210543080109" WEIGHT="46.47276395714992"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-18 12:48:21 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.0" STUDY_ID="STD-El_x002d_Bayoumi-2011" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.231241808530187" CI_START="0.14875819146981306" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6900000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2012-04-04 14:38:04 +0100" MODIFIED_BY="Richard Hughes" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.012466652225906314" Q="0.0" RANDOM="NO" SCALE="2.050988309019579" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="2.498652410103331">
<NAME>Change in disability grade after 4 weeks in patients with a history of diarrhoea</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.231241808530187" CI_START="0.14875819146981306" EFFECT_SIZE="0.6900000000000001" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.9" ORDER="1" SD_1="0.93" SD_2="1.08" SE="0.27614885416233836" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="24" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.069877625494936" CI_START="0.6901223745050642" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3800000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2012-04-04 14:38:23 +0100" MODIFIED_BY="Richard Hughes" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="8.832022900613955E-5" Q="0.0" RANDOM="NO" SCALE="2.3929608743258024" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="3.9206233086988695">
<NAME>Change in disability grade after 4 weeks in patients who were being ventilated at randomisation</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.069877625494936" CI_START="0.6901223745050643" EFFECT_SIZE="1.3800000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.58" ORDER="1" SD_1="0.78" SD_2="1.0" SE="0.3519848481587429" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-05-09 09:20:02 +0100" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>PE followed by IVIg compared with PE alone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.13537407667760892" CI_START="-0.5353740766776091" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2012-01-24 16:52:43 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.24247513730099735" Q="0.0" RANDOM="NO" SCALE="1.175068815691695" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="121" UNITS="" WEIGHT="100.0" Z="1.1688225899607287">
<NAME>Change in disability grade 4 weeks after randomisation</NAME>
<GROUP_LABEL_1>IVIg plus PE</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg with PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.13537407667760887" CI_START="-0.535374076677609" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.9" ORDER="18442" SD_1="1.4" SD_2="1.3" SE="0.1711123670245968" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="128" TOTAL_2="121" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.495731820974269" CI_START="0.5088506924116845" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5125" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="100.0" ID="CMP-003.02" LOG_CI_END="0.6528003968348575" LOG_CI_START="-0.2934096301858445" LOG_EFFECT_SIZE="0.1796953833245065" METHOD="MH" MODIFIED="2012-01-24 16:52:51 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4566126556260256" Q="9.97493724989993E-33" RANDOM="NO" SCALE="6.195645218818343" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="121" WEIGHT="100.0" Z="0.7444361599360784">
<NAME>Death</NAME>
<GROUP_LABEL_1>PE plus IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE plus IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.495731820974269" CI_START="0.5088506924116845" EFFECT_SIZE="1.5125" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6528003968348575" LOG_CI_START="-0.2934096301858445" LOG_EFFECT_SIZE="0.1796953833245065" ORDER="18443" O_E="0.0" SE="0.5558084536871337" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="128" TOTAL_2="121" VAR="0.3089230371900826" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5271728685917987" CI_START="0.45771219357028825" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8360655737704918" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.183888199876486" LOG_CI_START="-0.3394075177021473" LOG_EFFECT_SIZE="-0.07775965891283065" METHOD="MH" MODIFIED="2012-04-04 14:38:45 +0100" MODIFIED_BY="Ruth Brassington" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5602395873470727" Q="0.0" RANDOM="NO" SCALE="3.13695302416163" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="114" WEIGHT="100.0" Z="0.5824856798923286">
<NAME>Dead or disabled after 1 year</NAME>
<GROUP_LABEL_1>PE plus IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE plus IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5271728685917987" CI_START="0.45771219357028825" EFFECT_SIZE="0.8360655737704918" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.183888199876486" LOG_CI_START="-0.3394075177021473" LOG_EFFECT_SIZE="-0.07775965891283065" ORDER="1" O_E="0.0" SE="0.30738649486126796" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="122" TOTAL_2="114" VAR="0.09448645722309632" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1614460066386636" CI_START="0.4672550148304054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2154017857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.49988576903105714" LOG_CI_START="-0.33044602884375757" LOG_EFFECT_SIZE="0.0847198700936498" METHOD="MH" MODIFIED="2012-01-24 16:53:01 +0000" MODIFIED_BY="Ruth Brassington" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.689189277290321" Q="0.0" RANDOM="NO" SCALE="5.957652493180516" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="121" WEIGHT="100.0" Z="0.39995552280053687">
<NAME>Relapse or treatment-related fluctuation</NAME>
<GROUP_LABEL_1>PE plus IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE plus IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1614460066386636" CI_START="0.4672550148304054" EFFECT_SIZE="1.2154017857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.49988576903105714" LOG_CI_START="-0.33044602884375757" LOG_EFFECT_SIZE="0.0847198700936498" ORDER="1" O_E="0.0" SE="0.48774100828035427" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="128" TOTAL_2="121" VAR="0.2378912911583366" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.862620828396536" CI_START="0.6758670260783719" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.122" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.2701244550599564" LOG_CI_START="-0.17013874121967112" LOG_EFFECT_SIZE="0.049992856920142645" METHOD="MH" MODIFIED="2012-05-09 09:20:02 +0100" MODIFIED_BY="Ruth Brassington" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6562355911620871" Q="0.0" RANDOM="NO" SCALE="2.48" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="127" TOTAL_2="121" WEIGHT="100.0" Z="0.4451164661309104">
<NAME>Number improved by 1 disability grade after 4 weeks</NAME>
<GROUP_LABEL_1>PE plus IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>PE</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE plus IVIg</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.862620828396536" CI_START="0.6758670260783719" EFFECT_SIZE="1.122" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="70" LOG_CI_END="0.2701244550599564" LOG_CI_START="-0.17013874121967112" LOG_EFFECT_SIZE="0.049992856920142645" ORDER="1" O_E="0.0" SE="0.25861278083262274" STUDY_ID="STD-PSGBS-Study-Group-1997" TOTAL_1="127" TOTAL_2="121" VAR="0.06688057040998217" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-06-06 11:41:06 +0100" MODIFIED_BY="Richard Hughes" NO="4">
<NAME>Immunoabsorption (IA) followed by IVIg compared with IA alone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.31594889730419995" CI_START="-1.8840511026958002" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2014-06-06 11:41:06 +0100" MODIFIED_BY="Richard Hughes" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.005963706599627611" Q="0.0" RANDOM="NO" SCALE="2.1156595036266372" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="13" UNITS="" WEIGHT="100.00000000000001" Z="2.7497702325540123">
<NAME>Improvement in disability grade 4 weeks after randomisation</NAME>
<GROUP_LABEL_1>IA plus IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>IA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IA plus IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IA</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.31594889730419995" CI_START="-1.8840511026958002" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.5" MODIFIED="2014-06-06 11:41:06 +0100" MODIFIED_BY="Richard Hughes" ORDER="1" SD_1="1.63" SD_2="0.66" SE="0.400033423512011" STUDY_ID="STD-Haupt-1996" TOTAL_1="21" TOTAL_2="13" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-05-09 09:26:20 +0100" MODIFIED_BY="Richard Hughes" NO="5">
<NAME>IVIg versus immunoabsorption (IA)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.902690558854826" CI_START="-0.902690558854826" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2012-05-09 09:24:03 +0100" MODIFIED_BY="Richard Hughes" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.23" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Change in disability grade 4 weeks after randomisation</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>IA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours immunoabsorption</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.902690558854826" CI_START="-0.902690558854826" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.2" ORDER="1" SD_1="1.32" SD_2="1.5" SE="0.46056487056656853" STUDY_ID="STD-Diener-2001" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.453119289934833" CI_START="0.010395764220354247" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.7366449982174994" LOG_CI_START="-1.9831435790133005" LOG_EFFECT_SIZE="-0.6232492903979004" METHOD="MH" MODIFIED="2012-05-09 09:26:20 +0100" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.36904401531216724" Q="0.0" RANDOM="NO" SCALE="212.6" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="14" WEIGHT="100.0" Z="0.8982655290167951">
<NAME>Death</NAME>
<GROUP_LABEL_1>IVIg</GROUP_LABEL_1>
<GROUP_LABEL_2>IA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours immunoabsorption</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.453119289934833" CI_START="0.010395764220354247" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7366449982174994" LOG_CI_START="-1.9831435790133005" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="1" O_E="0.0" SE="1.5976172734359604" STUDY_ID="STD-Diener-2001" TOTAL_1="20" TOTAL_2="14" VAR="2.552380952380952" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>IVIg low dose (1.2 g/kg) versus high dose (2.4 g/kg)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2628967814216931" CI_START="-0.26289678142169304" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.19894823692449057" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.2845538428459298">
<NAME>Change in disability grade 4 weeks after randomisation</NAME>
<GROUP_LABEL_1>IVIg high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>IVIg low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2628967814216931" CI_START="-0.26289678142169304" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.3" ORDER="1" SD_1="1.3" SD_2="1.1" SE="0.3892402041258541" STUDY_ID="STD-Rapha_x00eb_l-2001" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2012-05-01 11:53:29 +0100" MODIFIED_BY="Richard Hughes" NO="7">
<NAME>Comparison of IVIg 1.0 g/kg daily for 2 days with 0.4 g/kg daily for 5 days</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9400139102843661" CI_START="-0.40001391028436606" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.27" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2012-05-01 11:53:29 +0100" MODIFIED_BY="Richard Hughes" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.42963300070612265" Q="0.0" RANDOM="NO" SCALE="1.37" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="0.7898198346377864">
<NAME>Disability grade change 4 weeks after randomisation</NAME>
<GROUP_LABEL_1>2-day regime</GROUP_LABEL_1>
<GROUP_LABEL_2>5-day regime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2-day regime</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-day regime</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9400139102843661" CI_START="-0.40001391028436606" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="-1.44" MEAN_2="-1.71" MODIFIED="2010-03-03 18:56:53 +0000" MODIFIED_BY="Richard Hughes" ORDER="41" SD_1="1.16" SD_2="1.23" SE="0.34185011335379134" STUDY_ID="STD-Korinthenberg-2005b" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-06-18 20:11:52 +0100" MODIFIED_BY="Ruth  Brassington">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-06-18 20:11:52 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdMAAAMXCAIAAADueihxAAA0aUlEQVR42u3dv24US96H8ZGQEIED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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-06-18 20:11:52 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 IVIg versus PE, outcome: 2.1 Change in disability grade 4 weeks after randomisation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0IAAADACAMAAAAeECMIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-06-18 20:11:52 +0100" MODIFIED_BY="Ruth  Brassington" NO="3" REF_ID="CMP-002.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 IVIg versus PE, outcome: 2.2 Number improved by 1 or more disability grades after 4 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAw4AAADgCAMAAACdOsEQAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-06-18 20:11:52 +0100" MODIFIED_BY="Ruth  Brassington" NO="4" REF_ID="CMP-002.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 IVIg versus PE, outcome: 2.3 Death.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAw4AAADwCAMAAACe7MOLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-06-18 20:11:52 +0100" MODIFIED_BY="Ruth  Brassington" NO="5" REF_ID="CMP-002.08" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 IVIg versus PE, outcome: 2.8 Number of patients with adverse events attributed to treatment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAw4AAADACAMAAACalsQmAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-03-07 09:44:18 +0000" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2014-03-07 09:44:09 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2013-12-02 21:46:19 +0000" MODIFIED_BY="Angela A Gunn">NMD Specialized Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-02 21:46:25 +0000" MODIFIED_BY="Angela A Gunn">
<P>#1 MeSH DESCRIPTOR Guillain-Barre Syndrome [REFERENCE] [STANDARD]<BR/>#2 ("Guillain Barre") AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#3 ("acute polyradiculoneuritis" or "acute polyneuritis") AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#4 MeSH DESCRIPTOR Polyneuropathies [REFERENCE] [STANDARD]<BR/>#5 MeSH DESCRIPTOR Polyradiculoneuropathy [REFERENCE] [STANDARD]<BR/>#6 (inflammatory NEAR neuropathy or inflammatory NEAR neuropathies) AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#7 (#1 or #2 or #3 or #4 or #5 or #6) AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#8 MeSH DESCRIPTOR Immunoglobulins, Intravenous [REFERENCE] [STANDARD]<BR/>#9 ("intravenous immunoglobulin*") AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#10 ("intravenous immunoglobulin*"ivig or "intravenous immune globulin*" or "intra venous immunoglobulin*") AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#11 ("intravenous immune globulin*" or "intravenous immunoglobulin*") AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#12 (#8 or #9 or #10 or #11) AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#13 (#7 and #12) AND (INREGISTER) [REFERENCE] [STANDARD]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-03-07 09:44:18 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<TITLE MODIFIED="2012-04-25 09:19:07 +0100" MODIFIED_BY="Angela A Gunn">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-15 15:57:12 +0100" MODIFIED_BY="Angela A Gunn">
<P>#1MeSH descriptor Guillain-Barre Syndrome explode all trees<BR/>#2"guillain barre"<BR/>#3MeSH descriptor Polyradiculoneuropathy explode all trees<BR/>#4"acute polyradiculoneuritis" or "acute polyneuritis"<BR/>#5landry* NEXT "ascending paralysis"<BR/>#6inflammatory NEAR neuropathy or inflammatory near neuropathies<BR/>#7inflammatory NEAR polyneuropathy or inflammatory NEAR polyneuropathies<BR/>#8(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)<BR/>#9MeSH descriptor Immunoglobulins, Intravenous, this term only<BR/>#10intravenous NEAR/3 immunoglobulin or intravenous NEAR/3 immunoglobulins<BR/>#11ivig<BR/>#12(#9 OR #10 OR #11)<BR/>#13(#8 AND #12)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-03-07 09:44:18 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<TITLE MODIFIED="2009-11-03 14:27:16 +0000" MODIFIED_BY="Angela Gunn">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-02 20:53:19 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Ovid MEDLINE(R) &lt;1946 to November Week 3 2013&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (390995)<BR/>2 controlled clinical trial.pt. (90070)<BR/>3 randomized.ab. (288395)<BR/>4 placebo.ab. (157299)<BR/>5 drug therapy.fs. (1772029)<BR/>6 randomly.ab. (200079)<BR/>7 trial.ab. (303857)<BR/>8 groups.ab. (1280166)<BR/>9 or/1-8 (3308511)<BR/>10 exp animals/ not humans.sh. (4066609)<BR/>11 9 not 10 (2817704)<BR/>12 guillain barre syndrome.tw. or Guillain-Barre Syndrome/ (6579)<BR/>13 acute polyradiculoneuritis.mp. or acute polyneuritis.tw. (175)<BR/>14 Polyneuropathies/ or Polyradiculoneuropathy/ (7836)<BR/>15 (inflammatory adj5 neuropath$3).tw. (1815)<BR/>16 (inflammatory adj5 polyneuropath$3).tw. (1408)<BR/>17 or/12-16 (14294)<BR/>18 intravenous immunoglobulin$.mp. or Immunoglobulins, Intravenous/ (13139)<BR/>19 ivig.tw. (4421)<BR/>20 intra venous immunoglobulin$.tw. (5)<BR/>21 intravenous immune globulin*.tw. (710)<BR/>22 or/18-21 (13849)<BR/>23 11 and 17 and 22 (646)<BR/>24 remove duplicates from 23 (580)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-03-07 09:44:14 +0000" MODIFIED_BY="Ruth Brassington" NO="4">
<TITLE MODIFIED="2012-05-08 11:49:40 +0100" MODIFIED_BY="Angela Gunn">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-02 20:44:28 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Embase &lt;1980 to 2013 Week 47&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure/ (39035)<BR/>2 double-blind procedure/ (118796)<BR/>3 randomized controlled trial/ (360573)<BR/>4 single-blind procedure/ (18539)<BR/>5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).tw. (1305866)<BR/>6 or/1-5 (1388815)<BR/>7 exp animals/ (19054215)<BR/>8 exp humans/ (15021100)<BR/>9 7 not (7 and 8) (4033115)<BR/>10 6 not 9 (1247713)<BR/>11 limit 10 to embase (964799)<BR/>12 guillain barre syndrome.tw. or Guillain Barre Syndrome/ (12013)<BR/>13 acute polyradiculoneuritis.mp. or acute polyneuritis.tw. (198)<BR/>14 Polyneuropathies/ or Polyradiculoneuropathy/ (13761)<BR/>15 (inflammatory adj5 neuropath$3).tw. (2425)<BR/>16 (inflammatory adj5 polyneuropath$3).tw. (1993)<BR/>17 or/12-16 (26238)<BR/>18 immunoglobulin/iv (19991)<BR/>19 intravenous immunoglobulin.mp. (9417)<BR/>20 ivig.tw. (7867)<BR/>21 intravenous drug administration/ and exp immunoglobulin/ (9429)<BR/>22 intravenous immune globulin*.tw. (953)<BR/>23 intravenous immunoglobulin*.mp. (11602)<BR/>24 or/18-23 (36895)<BR/>25 11 and 17 and 24 (256)<BR/>26 remove duplicates from 25 (256)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>